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ABSTRACT OF DISSERTATION

ESTROGEN REGULATION OF DAILY METABOLIC RHYTHMS IN FEMALE MICE

Circadian rhythms are approximately 24-hour cycles of behavior, physiology, and gene
expression. In mammals, these circadian rhythms are generated by clocks located in nearly
every tissue in the body. The function of circadian clocks is to synchronize physiology and
behavior with environmental cycles such as the light-dark cycle. After menopause, when
circulating levels of estrogens are very low, women are more susceptible to obesity
comorbidities such as metabolic syndrome and cardiovascular disease, suggesting that
estrogens regulate these processes. Estrogens could protect females from metabolic
dysfunction by regulating circadian rhythms. Consumption of diets that are high in fat contribute
to obesity. Consumption of high-fat diet (HFD) disrupts daily rhythms in male mice and they
develop diet-induced obesity (DIO). In contrast, previous studies have shown that female
C57BL/6J mice are resistant to HFD-induced obesity. Daily rhythms in female C57BL/6J mice are
also resistant to disruption by HFD feeding. Female mice maintain robust daily rhythms of eating
behavior and locomotor activity during HFD feeding. The circadian organization of molecular
rhythms in tissues in female mice are also protected from HFD-induced disruption. When
circulating estrogens are removed by ovariectomy (OVX), females are susceptible to DIO when
fed HFD, just like male mice. HFD feeding also disrupts daily rhythms in OVX females. The goal of
this dissertation was to investigate the role of estrogens in protecting daily rhythms in female
mice from disruption by HFD feeding. We found that estradiol replacement to physiological
levels in OVX females restored high-amplitude eating behavior and activity rhythms during HFD
feeding so they resembled intact females. Time-restricted feeding of OVX females at the proper
time of the day (12-hour active phase) inhibited obesity and improved glucose tolerance and
insulin sensitivity. We next investigated the mechanism by which estradiol signaling mediates its
protective effect against disruption of daily metabolic rhythms in female mice. We measured
the effects of HFD feeding on daily rhythms in global estrogen receptor α knockout (ERα KO)
female mice. We found that ERα was necessary to protect daily eating behavior and locomotor
activity rhythms from disruption by HFD feeding. The phases of circadian clocks in tissues were
also altered in ERα KO mice. The phases of PER2::LUC rhythms in the SCN and liver were
advanced in both male and female ERαKO mice compared to ERα WT mice fed low-fat diet. HFD
feeding exacerbated the phase advance of the live circadian clock in female ERα KO mice, but

not in ERα WT mice. Taken together these results shows that estrogen signaling via the ERα
receptor inhibits diet-induced obesity in part by regulating daily metabolic rhythms.

KEYWORDS: Estrogen, Diet-induced obesity, C57BL/6J mice, Daily rhythms, Estrogen receptors,
Circadian rhythms
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CHAPTER 1: INTRODUCTION
1.1.

Circadian Rhythms

1.1.1 Overview of Circadian Rhythms
Circadian rhythms are gene expression, physiology, behavior, and physical changes that
fluctuate approximately every 24 hours. Many living organisms, from microorganisms to plants
and animals, have circadian rhythms1,2. Circadian rhythms are endogenously generated, but
they also can be entrained to environmental cues such as light exposure and food availability3,4.
These rhythms allow the body to anticipate predictable changes in the environment to increase
fitness5 and for optimization of good health6,7,8. Circadian disruption that causes misalignment
between internal clocks and that external environment, such as jetlag, has been shown to
exacerbate cardiometabolic diseases and comorbidities like diabetes and stroke9,10.
Most species have endogenous circadian rhythms that are slightly shorter or longer than
24 hours11,12 that can be entrained to the external environment. The entraining or synchronizing
factors are referred to as zeitgebers or “time-givers.” A zeitgeber is an exogenous factor such as
light, temperature, exercise timing, and food timing that act as cues to entrain biological
rhythms. In many mammals, light is the strongest cue in the environment that synchronizes
circadian clocks.13,14 15.
Mammalian circadian rhythms are generated by clocks that exist in tissues all around
the body16. These clocks are organized in a hierarchy. The main clock is in the hypothalamus of
the brain in the suprachiasmatic nucleus (SCN)17,18.The SCN receives environmental light
information via the retino-hypothalamic tract (RHT)19. The SCN entrains to light-dark cycle and
then coordinates the phases of the circadian clocks in nearly every tissue in the body20 21. The
SCN thereby acts as the main clock to orchestrate the entrainment of internal clocks with the
external environment. The organization of the phases of these biological clocks in relation to
one another may be important in maintaining good health. For example, dysregulation of the
phases of circadian rhythms through shift work contributes to obesity and other comorbidities
like type 2 diabetes, cardiovascular disease, and cancer22-26.
1.1.2 Fundamental Properties of Circadian Rhythms
For any apparent rhythm to be considered a circadian rhythm it must have three
fundamental characteristics. The rhythm must: 1) Be endogenously generated with a period of
1

~24 hours.27,28; 2) Be entrainable by external cycles ,such as light and temperature, that have an
approximately 24-hour period. 293) Maintain its period of ~24 hours across a physiological range
of temperatures, known as temperature compensation30.
Parameters commonly measured in rhythms are amplitude, period, and phase (Fig. 1.1).
The amplitude measures the peak to trough of the rhythm. The period is the time to complete 1
cycle, or the duration between successive reference points on the waveform (e.g., peak to
peak). Finally, the phase is a particular point in the cycle or the timing between a set point of
day (e.g., beginning of night) and a set point on the waveform (e.g., peak).

Figure 1. 1. Parameters of a daily rhythm.
A rhythm showing its amplitude (peak to through), period (duration between 2 set points on
the waveform e.g., peak to peak), and phase (timing between a set point e.g., beginning of
night and set point on waveform e.g., peak).
Circadian rhythm and daily rhythm are often used interchangeably, although they are
different. Daily rhythms also have a period of ~24 hours. The key difference between circadian
and daily rhythms is that circadian rhythms are measured in constant conditions [e.g., constant
darkness (DD) or constant light (LL)] and daily rhythms are measured in the presence of a
zeitgeber. Since the daily rhythm is measured in the presence of a zeitgeber, it is impossible to
know if it is also circadian. Therefore, although circadian rhythms can be considered daily, not all
daily rhythms are circadian. It is however possible that some other factors such as geomagnetic
cues or even the rhythm of another true circadian rhythm could be entraining that said circadian
rhythm in LL or DD.
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The endogenous free-running period (Tau, τ) is measured in constant conditions, such as
DD. Tau in most organisms is ~24 hours and not exactly 24 hours. This ability of circadian
rhythms to persist and free-run (with a period that is slightly longer or shorter than 24 hours) in
constant condition shows that the rhythm is generated intrinsically and not just being entrained
daily by the environmental cue.
1.1.3 Entrainment and Phase Shifts
Although a circadian rhythm can persist in the absence of an external cue, alignment, or
a stable phase relationship of the rhythm with an external cue indicates the rhythm is entrained.
A strong zeitgeber that entrains circadian rhythms in mammals is light. The timing, intensity, and
duration of light exposure affect entrainment of circadian rhythms. In natural conditions, most
organisms are exposed to the predictable daily light/dark, temperature, or food availability
cycles. Thus, to maintain optimum fitness there is a need to entrain τ to the period of the
zeitgeber (T), i.e., τ=T. Entrainment implies that individuals of same species have similar
response to various condition such as light exposure. If entrainment happens, the phase (and
period) will be shifted to entrain with the new cue, and the rhythm will continue to free run
from the new phase.
There are 2 proposed mechanisms for circadian entrainment, namely the nonparametric
and parametric mechanisms. Pittendrigh developed the nonparametric (discrete) mechanism.
The non-parametric entrainment mechanism proposes that light pulses at different times of the
day are able to reset the internal clock as a result of daily phase shifts (by jumps or discrete
resetting) thus helping τ=T31. The time needed to be adjusted daily for any organism to have a
τ=T (i.e., to be entrained) is calculated as τ-T=Δφ, where Δφ is the phase shift. Since diurnal
organisms typically have free-running period of >24 hours, according to the non-parametric
entrainment, they need to phase advance daily (τ-T=+Δφ). In contrast, most nocturnal animals
will need to phase delay daily as a result of the <24h free-running period (τ-T=-Δφ).
A phase response curve (PRC) can be used to predict the entrainment of an organism to
different zeitgebers, e.g., light pulese12. The PRC shows the phase shift in hours in relation to the
CT time the pulse was given. Light pulses in the subjective day usually have no effect on
circadian phase while light pulses given in the subjective night will have a phase resetting effect.
This could be an advance or delay depending on if the organism is nocturnal or diurnal and on
the circadian time the light pulse was applied. Typically, light exposure to a nocturnal organism
3

during its early active phase will cause a delay while light during the late active phase will cause
an advance. The opposite is true for diurnal organisms.
Aschoff proposed the parametric (continuous) entrainment mechanism11,32,33. In the
parametric mechanism, the intensity and duration of light slows down or speeds up the freerunning period. Aschoff generated a set of general “rules” that were based on his extensive
observations of circadian rhythms in diurnal and nocturnal animals. His first 2 rules are that
diurnal animals have free-running periods longer than 24h and nocturnal animals have freerunning periods shorter than 24h. His model of parametric entrainment was reflected in his 3rd
and 4th rules, namely that increasing light intensity and duration (to constant light) reduces the
free-running period in diurnal animals but increases period in nocturnal animals. It should be
noted that while Aschoff’s rules are often correct, there are exceptions.
1.1.4 Molecular Circadian Timekeeping Mechanism in Mammals
The molecular mechanism of the mammalian circadian timekeeping mechanism is a
negative feedback loop of transcription and translation (TTFL)34. The transcription factors brain
and muscle Arnt-like 1 (BMAL1) and circadian locomotor output cycles kaput (CLOCK)
heterodimerize and bind to enhancer elements in the promoter region (E-boxes) of the Period
(Per) and Cryptochrome (Cry) genes35 (Fig. 1.2). After translation, PER and CRY translocate to the
nucleus and inhibit their own transcription by inhibiting the transcriptional activity of BMAL1
and CLOCK. This negative transcription-translation feedback loop takes approximately 24 hours
to complete thus generating the 24-hour circadian rhythm35 (Fig. 1.2).
Other genes can also be translated by the action of BMAL1/CLOCK on E-boxes. The
BMAL1/CLOCK heterodimer binds to the E-box of Rorα and Rev-erbα and drive their
transcription36,37. RORα and REV-ERBα are then translocated back into the nucleus where they
individually block (REB-ERBα) or stimulate (RORα) Bmal1 transcription by competitively binding
to the receptor response elements (RREs)36,37.
The circadian clock machinery is present in almost all cells in the body and controls the
rhythmic expression of thousands of genes that do not participate in the core timekeeping
mechanism. BMAL1/CLOCK binds to E-boxes that are present in many non-circadian genes,
which are called clock output genes. About 40% of mammalian genes are under circadian
control38. The TTFL can therefore control rhythmic expression of many genes in the body.
4

The effects of disrupting the molecular circadian timekeeping mechanism have been
shown in several studies. Both Per and Clock mutations have been shown to affect free-running
period by shortening and lengthening FRP respectively3,39. Both mice40 and humans41 with a
single point mutation in their Per2 gene have shortened periods. Bmal1 KO mice are arrhythmic
in DD42.

Figure 1. 2. Mouse molecular circadian timekeeping mechanisms.
The molecular circadian timekeeping mechanism is a negative transcription and translation
feedback loop (TTFL). BMAL1 and CLOCK drive transcription of Per and Cry genes at their Eboxes. PER and CRY then inhibit transcriptional activity of CLOCK-BMAL1. BMAL1 and CLOCK
also drive transcription of Rorα and Rev-erbα genes at their E-boxes. ROR and REVERBs then
upregulate or downregulate, respectively, Bmal1 transcription.
1.1.5 Circadian Organization of Clocks in the Body
The SCN in the hypothalamus is the main circadian pacemaker in mammals. Ritcher first
localized the ventral hypothalamus as the brain region necessary for maintenance of circadian
rhythmicity43. The SCN was discovered in the 1972 by two labs. Moore and Eichler showed that
5

lesioning the SCN eliminated the circadian rhythm of corticosterone in rats17. Stephan and
Zucker also showed that SCN lesion caused rats to lose their endogenous free-running drinking
rhythms18,44. Studies in other animals, e.g., mice show the same results45,46. Green and Gillette
also found that cultured SCN slices maintained circadian rhythms of neuronal activity ex vivo,
demonstrating that the rhythm is generated endogenously by SCN cells47. Transplantation
studies also showed that the SCN encodes an individual’s circadian period48. SCN transplants
restored rhythms of locomotor activity in SCN-lesioned hamsters, but they displayed the period
of the donor and not their initial periodicity49,50.
The mouse SCN has 2 nuclei each containing ~10,000 neurons. The SCN is divided into
the ventral/core region and the dorsal/shell region based on the major neuropeptides present51.
The SCN core is vasoactive intestinal polypeptide (VIP)-containing while the shell mostly
contains arginine vasopressin (AVP)52. There are more neuronal projections from the core to the
shell region than vice-versa53. The core has been shown to be important in coupling of the cells
within the SCN cells and targeted ablation of the core results in arrhythmic body temperature,
locomotor activity, and cortisol54. AVP has also been shown to be involved in determining
circadian period55. Studies have shown that each cell in the SCN has a circadian rhythm, and
these individual cells are coupled to each other. This strong coupling is responsible for the
sustained rhythmicity of SCN tissue in culture56.
There are also circadian clocks in nearly every tissue in the body. Population sampling
first showed that tissues in vivo had rhythms of circadian gene expression, e.g., the TTFL, but
this did not show they were sustained endogenously57. Evidence of self-sustained rhythms in a
peripheral tissues was first reported in the intestine of golden hamsters58. Tosini and Menaker
showed that hamster retina could free-run in DD and had a free-running period similar to that of
the animal it was cultured from59. Finally, using Per1-luc rats, self-sustained rhythms in other ex
vivo peripheral tissues were recorded60. Cultured peripheral tissues from transgenic Per1-luc
rats had circadian rhythms for about a week while SCN cultures from same rats continued to
have a rhythm for about a month21. The molecular circadian TTFL has been found in almost all
cells of the mammalian body10,59,61,62. The cellular clocks within tissues are coordinated with
each other to generate tissue-level rhythms.
The SCN is at the top of hierarchical organization of circadian clocks in mammals.
Information about the level of light in the environment is detected primarily by the intrinsically
6

photosensitive retinal ganglion cells (ipRGCs)63. The SCN then receives input about the light/dark
cycle directly from the ipRGCs in the retina via the retinohypothalamic tract (RHT)14,60,64 65 (Fig.
1.3). The SCN then acts as the conductor in the orchestra to coordinate or synchronize the
timing of the clocks in various tissues around the body to that of the external environment (Fig.
1.3). The mechanisms by which the SCN coordinates the phases of body clocks have not been
fully elucidated, but includes peptide signals, neural projections to brain regions such as the
paraventricular nucleus (PVN), and the via temperature rhythms (Fig. 1.3)3,10.
Circadian organization, or the phase relationship between tissue clocks, can be
measured in circadian reporter transgenic animals60,66. Bioluminescence is often used as a
circadian reporter because these rhythms persist over a period of days in vitro66. The first
reporter mammals were the Period1-luciferase rats, which were generated by Tei21. Several
years later, the Takahashi lab developed the PERIOD2::LUCIFERASE mice, in which the luciferase
gene was knocked in to the 3’ terminus of the Period2 gene, thereby created a fusion protein60 .

Figure 1. 3. Organization of the circadian system in mammals.
The suprachiasmatic nucleus (SCN) receives light/dark information and coordinates the
phases of molecular clocks in tissues. On the cellular level, the circadian molecular clock is a
transcriptional-translational feedback loop of circadian mRNA and protein expression.
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1.2 Estrogens in Mice
Estrogen is derived from the Greek words ‘oistros’ (in heat) and ‘gennan’ (to produce)
and was first discovered in the early 1920s when ovarian extracts from cattle affected sexual
receptivity and fertility of rodents67. Estrogen is a steroid hormone derived from cholesterol that
is synthesized in the gonads, brain, white adipose tissue, and placenta. However, most
estrogens are synthesized in the gonads and function as endocrine factors68.Menpause is the
period when ovaries stop producing reproductive hormones and this leads to cessation of
menstruation. Estrogen levels decline during menopause in women69. In female rodents
however, there is no significant decrease in estrogen level as aging occurs70. Instead, there is
decreased estrous cyclicity or the mice become acylic70,71.
1.2.1 Synthesis and degradation of estrogens
There are three major types of natural endogenous estrogens in the mammalian body,
namely estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4). E1 and E2 are synthesized in
the mouse while E3 and E4 are produced in detectable amounts in pregnant humans. E1 is
synthesized by adipose tissue and gonads and can be made from estradiol or converted to
estradiol69 (Fig. 1.4). E1 has lower binding affinity to the estrogen receptors (ERs) compared to
E269. E2 is the primary female sex hormone present during the reproductive years. Among all
the estrogen forms, estradiol has the highest affinity for estrogen receptors.
In female mice, gonadal estrogens are produced in the thecal and granulosa cells of the
ovary (Fig. 1.4). The thecal cells express luteinizing hormone (LH) receptors and binding of LH to
its receptor facilitates the transport of cholesterol into the inner mitochondrial membrane72.
The shuttling of cholesterol into the mitochondria is the rate-limiting step in the production of
estrogens72. In the mitochondria, cholesterol is converted to pregnenolone by the cytochrome
P450 side chain cleavage enzyme (CYP11A). Pregnenolone can then be converted to 17αhydroxypregnenolone and consequently to dehydroepiandrosterone (DHEA) by 17α-hydroxylase
(CYP17). Alternatively, pregnenolone can be converted to progesterone by 3β-hydroxysteroid
dehydrogenase (3β-HSD). Progesterone is converted to 17α-hydroxyprogesterone and then to
androstenedione by CYP17. DHEA is also converted to androstenedione by 3β-HSD. Then,
testosterone is synthesized from androstenedione (4A) by 17β-hydroxysteroid dehydrogenase
(17β-HSD). Androstenedione can also diffuse across the basal lamina of the ovarian follicle into
the granulosa cells. Androstenedione (or testosterone) is then converted to estrone by CYP19
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(aromatase) in the granulosa cells. Activation of the follicle-stimulating hormone (FSH)
receptors, which are expressed on the granulosa cells, influences the expression of aromatase
and 17β-HSD in the cell73. Estradiol, which is the biologically active form of estrogen, is then
made by 17β-HSD from estrone in the granulosa cell (Fig. 1.4).
Estrogens can also be produced in other tissues expressing aromatase such as the
adipose tissue, skeletal muscle, bone, and liver74-76. After ovariectomy (OVX), which is the
removal of the ovaries, estrogen is still produced in extra-gonadal tissues and acts locally as a
paracrine or intracrine factor77. Extra-gonadal sites of estrogen production are incapable of
producing C-19 steroids (such as testosterone and DHEA) but have the enzyme (aromatase) to
convert testosterone to estrogen77-79 (Fig. 1.4). Thus the rate of paracrine/intracrine estrogen
production depends on availability of C-19 steroids and aromatase level in the cells73.
Estrogens are metabolized primarily in the liver, and in select tissues such as the brain,
uterus, and kidney80. A sub-type of 17β-HSD (HSD17B2) catalyzes the transformation of the
potent estradiol (and estrone) to the less potent estriol via dehydrogenation followed by
hydroxylation catalyzed by the cytochrome P450 family81. Tissues expressing these enzymes are
therefore capable of metabolizing estrogens82. Estrogens can be conjugated by estrogen
sulfotransferases (EST) by sulfation to produce biologically inactive form of estrogen with almost
no binding affinity to the estrogen receptors83-85 (Fig. 1.4). These highly soluble metabolized
products of estrogens can then be excreted via urine or feces86. The serum half-life of E2 is
about 2 hours in rats87. Estrogen conjugates can however be reconverted to estradiol and
therefore act as a reservoir for circulating estrogens thus increasing the half-life of estrogen in
the system83,69.
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Figure 1. 4. Synthesis and metabolism of steroid hormones.
In the thecal and granulosa cells of the ovary, cholesterol is converted to pregnenolone by the
cytochrome P450 side chain cleavage enzyme (CYP11A). Pregnenolone is then converted to
progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD) or to 17α-hydroxypregnenolone
by 17α-hydroxylase (CYP17). Progesterone can diffuse across the basal lamina from granulosa
to thecal cell. Granulosa cells lack CYP17 which is necessary to convert progesterone to 17αhydroxyprogesterone and then to androstenedione (4A). CYP17 also catalyzes the conversion
of pregnanolone to 17α-hydroxypregnenolone and then to dehydroepiandrosterone (DHEA).
3β-HSD catalyzes the conversion of DHEA to 4A which is then converted to testosterone (T) by
117β-hydroxysteroid dehydrogenase (17β-HSD). 4A and T can be shuttled to the granulosa
which contains aromatase (CYP19) necessary for estrogen synthesis. Peripheral tissues like
WAT do not express CPY11A and CPY17 necessary for synthesis of DHEA, 4A and, T, but
contain enzymes for synthesis and metabolism of estrogens.
1.2.2 Estrogen receptors
The first estrogen receptor (ER) was cloned in 1986 and since then, several other
estrogen receptors have been discovered88. In mammals, the ERs are ERα, ERβ, ER-X, and the G
protein-coupled estrogen receptors GPER1, and Gq-mER. Different ERs have different
subcellular locations and are present in the nucleus, cytoplasm, plasma membrane, or
associated with specific organelles like the endoplasmic reticulum. Estrogen signaling
mechanisms are categorized into either genomic or non-genomic signaling. Estrogens can
mediate transcriptional (genomic) events by direct binding of ERs to DNA sequences in the
nucleus or via indirect signaling pathways. The genomic effects of estrogen signaling are slow,
10

i.e., it takes time for gene expression to be changed. Estrogens can also mediate rapid nongenomic actions by activating signaling cascades via binding with ERs on the cell membrane.
1.2.2a ERα and ERβ
Estrogen receptors (ERs) are found in nearly every tissue of the mammalian body75,89.
Estrogen receptor α (Erα) has been shown to be the receptor by which estrogen exerts its
reproductive effects. ERα is highly expressed in the female and male reproductive organs,
bones, liver, skeletal muscle, and adipose tissue75,90. ERα is also highly expressed in parts of the
brain associated with regulating energy balance91,92. Estrogen receptor β (ERβ) is found mainly in
the bladder, ovary, colon, adipose tissue, brain and immune cells75.
Mammalian ERs are encoded by different genes on different chromosomes93,94 (Fig. 1.5).
The ESR1 (Estrogen Receptor 1) gene encodes ERα95,88. ERβ is encoded by the ESR 2 (Estrogen
Receptor 2) gene96. Mammalian ERα and ERβ have 6 different domains (A-F; from N to C
terminus) specific for transcription activation (Domain A, B: AF-1), DNA binding (Domain C),
ligand binding (Domain E: AF-2), and ligand differentiation (Domain F)88,97. Domain C (and E) is
highly conserved in both ERα and ERβ resulting in their high affinity for estrogen response
element (EREs). There is little conservation of sequences in AF-198. ERβ-mediated transcriptional
activation of genes is lower than that of ERα. This is because the AF-1 domain of ERβ is nonfunctional97. Alternate splice forms of ERs also exist with different lengths of AF-1. Based on the
homology of the ER sequences (specifically the AF2 domain), ERα and ERβ have different
specificity for the different types of ER ligands.
Estrogens exert their direct genomic effects mainly by binding to cytoplasmic or nuclear
ERα and ERβ. Individual ERs in the cells are stabilized by heat shock proteins (HSP). After binding
to the ligand, ERs dimerize either as homodimers (ERαα or ERββ) or heterodimers (ERαβ) and
translocate to the nucleus. ERs in the nucleus can directly bind to specific sites on the DNA, the
estrogen response elements (ERE), which are short palindromic repeats of DNA sequences in the
promoter regions of target genes97 (Fig. 1.6)97EREs then interact with coactivators and
transcription factors to regulate gene expression. The interaction of AF-1 and AF-2 with
coactivators and transcription factors leads to differences in ER-mediated signaling93,99. ER
activity can also be affected by sequences besides the bound ERE or by variation in the ERE
sequence itself97. The ERE sequence (and the type coactivators/transcription factors that can be
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recruited), types of ERs located in a tissue, and available transcription factor/co-regulatory
proteins all play a role in the action of estrogen signaling in different tissues.

Figure 1. 5. Domains in ERα and ERβ.
The 6 domains of the ERs: N terminal A/B domain, the DNA-binding C domain, the hinge D
region, the ligand-binding E domain, and the C terminus F region. The greatest homology
between ERα and ERβ is seen in Domain C. AF-1 and AF-2 are important for receptor-specific
function.
ERα and ERβ can also be tethered to the plasma membrane via anchor proteins as a
result of post-translational modification100,101. Membrane-bound and nuclear ERα and ERβ are
encoded by the same genes, respectively, but membrane-bound forms are pamitoylated on
their of cystein residue and associate with Hsp 27102. Studies have shown that anchor proteins
Shc, insulin-like growth factor 1 (IGF-1R), and striatin allow for the localization of ERs (mainly
ERα) to the plasma membrane103,104. These membrane-bound ERs-E2 complexes then interact
with scaffolding proteins such as caveolin-1100.
ERs located on the plasma or organelle membranes have indirect non-genomic rapid
signaling pathways101,105-107 (Fig. 1.6). ERα and ERβ often do this by activating various signaling
pathways including cellular Ca2+ influx, K+ efflux, and activation of protein-kinases signaling
cascades100,107. These protein-kinases pathways include (PI3K)/AKT, Ras/Raf/MAPK, and
PKA100,107. This rapid cascade signaling has been shown to be mostly mediated by ERα93.
E2 binding to ERα, Erβ, located on the plasma membrane also mediates indirect
genomic signaling pathways to control functions such as cell differentiation, growth, and death
101,105-107

(Fig. 1.6). In this case, the ER tethers a DNA-bound transcription factor via protein-

protein interaction to stabilize the DNA-transcription factor bond and/or to recruit
coactivators97,108,109. For example, the transcription factor stimulating protein-1 (Sp-1) binds to a
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promoter region and mediates indirect genomic action of ERs. Binding and transcriptional
activation of Sp-1 is thus increased in the presence of ERs.
ERs can also be activated by ligand-indepenent mechanisms, such as phosphorylation of
specific amino acids of the ER or as a result of phosphorylation of an associated transcription
factor (i.e PKA and PKC)110,111(Fig. 1.6). In general, the ligand-independent activation of both
ERα and ERβ has been shown to be as a result of serine residue phosphorylation in the Nterminal AF-1 domain. The AF-1 has been shown to respond to EGF-induced activation of the
ER112. The mechanism for this is a direct result of MAPK or AKT induced phosphorylation of
various serine residues in AF-1 domain. This shows that the actions of nuclear (n-ERs) and
membrane (m-ERs) bound ERs are not mutually exclusive as evidence shows that rapid kinase
signaling of E2 via m-ER can cause phosphorylation of n-ERs and its coactivators100,110,113.
1.2.2b GPER1, Gq-mER, and ERX
GPER1 is highly expressed in the kidneys, pancreatic cells, hypothalamus, breast, brain,
immune cells, and pituitary114. GPER1 mediates rapid non-genomic signaling via protein-kinase
cascades on the plasma membrane105-107,115. Similar to cell membrane bound ERs (m-ERα, m-ERβ
and GPER), binding of estrogens to GPER1 on the endoplasmic reticulum also causes rapid
calcium influx into the endoplasmic reticulum which activates protein-kinase cascades105.
Although Gq-mER has not been as well studied, it has been found in the and proopiomelanocortin (POMC) neurons and was shown to control energy homeostasis116,117. GqmER activates protein-coupled inwardly rectifying K+ (GIRK) channels and thereby functions to
reduce sensitivity of the cell to GABA agonist118,119. Gq-mER is also activates PKA and PKC
pathways118.
ER-X has been shown to be highly expressed post-ischemia and in the uteri and lungs of
postnatal rodents, with almost no expression in adults otherwise120. The weaker 17α-estradiol
(E1) has a higher affinity for activating the ERX-induced MAPK/ERK pathway than E2120. ERX has
not been well studied.
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Figure 1. 6. Estrogen receptor (ER) signaling mechanism.
The four ER signaling mechanisms are: 1. Direct genomic signaling via classical nuclear
receptors: E2 binds the ERs leading to their dimerization and translocation into the nucleus
where they induce transcriptional changes by binding to EREs of target genes. 2. Indirect
genomic signaling: Membrane bound estrogen receptors (ERs) modulate membrane ion
channels, secondary messenger cascades, and phosphorylation of transcription factors (TF). 3.
Ligand or E2-independent: Growth factors such as EGFR and IGFR bind to their receptors and
activate protein kinase cascades that can phosphorylate and activate ERs, which then bind
EREs and regulate gene transcription. 4. ER-independent: E2 can exert its antioxidant effect
without ERs.
1.2.3. The Mouse Estrous Cycle
The estrous cycle in female mice is a series of physiological changes that occur as a
result of the regular fluctuations of reproductive hormones. Estrous cycles begin after sexual
maturity is attained, which is about 6 weeks old in most female mice. The mouse estrous cycle
repeats every 4-5 days and is classified into 4 stages, namely proestrus, estrus, metestrus, and
diestrus121.
The fluctuations in hormones during the estrous cycle in mice are well characterized.
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels begin to rise in the
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evening, and LH and FSH peak in the late night of proestrus122 (Fig. 1.7). An increasing pulsatile
LH release occurring during late afternoon of proestrus leads to an LH surge or peak LH level123.
This LH surge then induces ovulation during the same night in rodents124,125. The estrus (or heat)
stage is the post-ovulatory stage which could last less than 24hrs and is also characterized by
reducing E2 and peak prolactin (PRL) levels126,127 (Fig. 1.7). During metestrus, progesterone
begins to rise alongside with a second (but smaller) estrogen peak. The diestrus stage could
occur for longer than 24hrs and is characterized by peak progesterone level (Fig. 1.7). The timing
of the LH surge is under circadian control by the SCN128. This will be discussed in a later section.
Figure 1. 7. Schematic diagram of
hormone levels during the 4-day
mouse estrous cycle.
Fluctuating levels of circulating
hormones: luteinizing hormone (LH),
follicle- stimulating hormone (FSH),
Prolactin (PRL), progesterone (P4), and
17-beta-estradiol (E2) (adapted from
McLean et. al. 2012).

GnRH

Physiological and anatomical changes can be used to determine the estrous stage of
mice. Levels of LH, FSH, E2, and progesterone can be measured in blood samples to determine
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the stage of estrous cycle. However, measuring hormones is challenging since levels are
sometimes below the level of detection of standard assays. Other methods, such as the size of
the vaginal opening and vaginal cytology, are straightforward and can be performed daily in live
animals 122,127.
1.2.4. Hypothalamic–pituitary–gonadal regulation of reproductive hormones and the estrous
cycle
The hypothalamic–pituitary–gonadal axis (HPG axis) coordinates reproductive hormones
during the estrous cycle. In 1955, Harris proposed that a humoral substance released in the
hypothalamus controlled gonadotropic hormone release129. In 1971, Gonadotropin hormonereleasing hormone (GnRH) was isolated and reported to regulate the release of LH and FSH from
the anterior pitutary130,131 (Fig. 1.8).
GnRH peptide is released from neurons in the medial preoptic area (POA) and
arcuate/infundibular nucleus of the hypothalamus and secreted into the capillaries of portal
venous circulation where it is delivered to the anterior pituitary (Fig. 1.8)132,133. GnRH can be
released in pulsatile fashion or in surges134. The pulsatile mode of GnRH release occurs
throughout the entire estrous cycle while the surge mode occurs just before ovulation 134,135 (Fig.
1.7).
GnRH binds to its receptors in the pituitary where it stimulates the gonadotrophs to
secrete LH and FSH133 (Fig. 1.8). FSH stimulates granulosa cells on some primary ovarian follicles
and causes them to mature. LH stimulates the thecal cells of the secondary follicle usually
leading to a graffian follicle. Just before ovulation, the highest level of circulating estrogens is
produced by the follicle(s) and it feeds back positively on the GnRH neurons and increases GnRH
release (Fig. 1.7). This GnRH pulse results in positive feedback on FSH and LH levels causing them
to increase and surge. The LH surge is responsible for the release of the mature follicle, i.e.,
ovulation. After ovulation, E2 levels are low because the follicle atrophies. The corpus luteum,
formed from the granulosa cells after ovulation, is stimulated by LH (and FSH) to release
progesterone and some estrogen (Fig. 1.4). Progesterone also functions to inhibit LH and FSH
levels via negative feedback (Fig. 1.7).
Kisspeptin is a neuropeptide stimulates GnRH neurons. Mutations affecting either the
gene encoding kisspeptin or its G-coupled receptor (the Kiss1 and Kiss1r) have been shown to be
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involved in delayed sexual maturation and abnormal estrous cycles in mice136,137. Kisspeptin
neurons are localized mainly in the arcuate nucleus (ARC) and the anteroventral periventricular
nucleus (AVPV)/ preoptic periventricular nucleus (PeN), together referred to as the rostral
periventricular region of the third ventricle (RP3V)138-140. Two neuropeptides, dynorphin (dyn)
and neurokinin B (NKB), which play opposite roles, have been shown to be colocalized with
kisspeptin in the mammalian hypothalamus141,142. Co-expression of neurokinin B, dynorphin and
Kiss is present only in the ARC141,143,144. NKB released by the KNDy neurons stimulates both KNDy
(to release Kiss, NKB, and Dyn neuropeptides) and GnRH neurons (to release GnRH) while Dyn
acts on both KNDy and GnRH neurons to inhibit release of their peptides143,145 (Fig. 1.8).
GnRH neurons do not express ERα but Kiss neurons from both the RP3V and ARC area
projecting to GnRH neurons do express ERα and PR146-151. The majority of GnRH neurons express
the kisspeptin receptor (Kiss1r)152. E2 signaling via ERα on the Kiss neurons in the RP3V area
activates the E2 positive feedback mechanism on the HPG axis leading to increased stimulation
of the GnRH neurons (i.e., pulses)148,153,154. RP3V Kiss1 mRNA expression and firing of RP3V
neurons also only increases in proestrus when E2 levels are increased during E2 positive
feedback155. The preovulatory GnRH/LH surge is thereby activated via these Kiss1 neurons in
the RP3V area147. Negative feedback of estrogen (and progesterone) is done via KNDy neurons
of the ARC148,154 (Fig. 1.8). ARC Kiss1 mRNA expression increases when the E2 level is low 148,154.
Progesterone is at its lowest levels during proestrus/estrus and peaks during diestrus.
Progesterone is known to act via its receptor reduce both GnRH and LH pulses156,157.
Progesterone receptors (PR) are found to be colocalized on both the GnRH and KNDy neuron157. Progesterone increases the release of dyn (which represses GnRH) from the KNDy
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neurons160. Therefore, low progesterone decreases dyn level leading to increased GnRH pulses
and LH levels 160,161 (Fig. 1.8).
PRL release from the lactotrophs in the anterior pituitary and regulated by
tuberoinfundibular (TIDA) neurons in the ARC is stimulated by E2 and repressed by dopamine162. At high levels, PRL represses the LH surge thus preventing ovulation166,167 (Fig. 1.7). PRL
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receptors are expressed on the ARC Kisspeptin neurons and thus can suppress GnRH and LH
pulses168-170. Anovulatory hyperprolactinemic mice have reduced Kiss1 mRNA expression and
Kisspeptin administration is able to rescue this phenotype167.
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1.2.5. Effects of Disrupting Estrogen Signaling on the HPG Axis
Disruption of estrogen signaling alters the finely controlled feedback system in the HPG
axis. Estrogen signaling can be disrupted in several ways. First, ovariectomy, which is removal of
the ovaries, eliminates estrogens in systemic circulation. Second, estrogen signaling can be
disrupted by knocking out estrogen receptors. Third, the synthesis of estrogens can be inhibited
by knocking out aromatase.
Ovariectomy removes nearly all circulating estrogens in mice since the ovaries are the
primary source of circulation estrogens. Since circulating estrogen plays a key role in regulating
the HPG axis, ovariectomy affects the feedback control cycles of the HPG. The lack of circulating
estrogens causes OVX mice to have increased GnRH and LH pulse frequency throughout the
day171 leading to increased systemic LH and FSH levels172,173.
In ovariectomized mice that are implanted with Silastic tubing containing estradiol,
which keeps the estradiol level constant and elevated, there is a daily transition from positive to
negative estrogen feedback on the LH surge171,172. LH and GnRH pulses frequency are lower
during the day as a result of estrogen negative feedback and higher at night due to estrogen
positive feedback since increased GnRH pulses and the LH surge begins at start of the active
phase174. This treatment with proestrus E2 levels results in proestrus GnRH/LH surge occurring
in late afternoon to early night and results in slightly elevated LH level and elevated FSH
levels175.
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Figure 1. 8. Neural circuit of the Kisspeptin-GnRH-LH/FSH pathway in rodents.
Kisspeptin in the RP3V and KNDY neurons in the ARC directly signals and stimulate Kisspeptin
receptor (Kiss1-R) on GnRH neurons in the POA via pulsatile kisspeptin secretion. Autocrine
signaling of the KNDY neurons also inhibits (via Dyn) or stimulates (via SKB) pulsatile release
of Kisspeptin. GnRH neurons in the POA then secretes GnRH in pulses to stimulate its receptor
(GnRH-R) on the gonadotrophs of the pituitary to release luteinizing hormone (LH) and follicle
stimulating hormone (FSH). In females, FSH then stimulates the follicles via its receptor (FSHR) to mature while LH surge leads to ovulation via the LH receptor (LH-R). **Rostral
periventricular region of the third ventricle (RP3V) comprises of the anteroventral
periventricular nucleus (AVPV) and preoptic periventricular nucleus (PeN). Kisspeptin neurons
co-expressing neurokinin B (NKB) and dynorphin (DYN) (KNDy neurons). Arcuate nucleus
(ARC). Preoptic area (POA).
ERα has been shown to be the receptor via which estrogen exerts its reproductive
effects. Studies indicate that ERα KO mice are insensitive to circulating estrogen in regards to
reproduction, obesity, and several other phenotypes90. Homozygote ERα KO males and females
are infertile. Female ERα KO mice do not develop normal secondary sexual characteristics and
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male ERα KO mice have small testes89,176,177. Exogeneous estradiol reduces LH levels in wild-type
ovariectomized mice but not in ovariectomized ERα KO female mice178. Whole-body ERα KO
females have a 4x elevated LH level (compared to wild-type mice) 178 and elevated estrogen and
FSH levels179. These mice, however, do not experience LH surges and are anovulatory179. This is
most likely due to the inability of E2 to stimulate ERα in the RP3V and thus activate the positive
feedback loop (Fig. 1.8).
Although ERβKO females are able to successfully become pregnant and have pups, their
litter sizes are smaller compared to WT mice180. This subfertility has been attributed to an
increased number of atrophic follicles and fewer corpus luteum180. ERβKO females have lower
estrogens levels181,182. This results in less frequent GnRH and LH pulses181. This results in less
frequent GnRH and LH pulses181, therefore these mice have lower FSH and LH. ERα level has
been shown to be responsive to level of E2 in the body183.
Knocking out aromatase is a genetic way to remove circulating estradiol. Aromatase KO
(ArKO) mice were generated by disruption of the cyp19 gene184. ArKO female mice lack
circulating estrogens and estradiol treatment increases their uterine weight comparable to wildtype females184,185. These female mice have 10x the normal testosterone level and LH level while
their FSH is also elevated by ~3x186-188. ArKO male mice are fertile while females are infertile 184.
1.2.6. Circadian Timing of Hormone Secretion
The circadian system regulates the timing of reproductive hormone secretion. To ensure
that maximum reproductive success of a female is attained, it is important that the timing of
highest fertility (i.e., ovulation) aligns with sexual receptivity. Therefore, the rising (and
sustained high) E2 level, and the neural signal that leads to the GnRH (and LH) surge needs to be
properly timed. The SCN acts as the main pacemaker17,18 to orchestrate this timing124. SCN
control of hormone rhythms requires neural projections as the proper hormonal rhythms are
not restored to SCN-lesioned animals after SCN transplant189,190.
There are direct SCN neural projections to the ARC, AVPV, and PVN.191,192. The SCN
peptide, AVP, regulates Kiss1 neurons in the RP3V area 124 and gonadotropin-inhibitory hormone
(GnIH)193. AVP is rhythmically synthesized in the SCN and has lower mRNA expression at night
and its peak level correlates to the timing of LH surge194. The preovulatory LH surge occurs
during the early active phase in mammals (early evening for nocturnal animals and early
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morning for diurnal animals)171,195. LH and FSH also surge at the beginning of the night123. AVP
administration to SCN-lesioned mice induces the LH surge196. This shows an interaction of the
circadian clock system and circulating hormone in the timing of estrous cycle in rodents197,198.
The SCN also has VIP neurons. VIP-expressing SCN neurons directly innervate GnRH
neurons and VIP antisense oligonucleotides can both delay and reduce the amplitude of LH
surges199,200. GnRH neurons fire at a higher rate in the evening/night and thus an increased
GnRH pulse is seen in the evening as compared to morning in mice201. This is indicative of an
estrogen positive feedback loop increasing firing of the GnRH neuron at night and the negative
feedback loop decreasing firing of the GnRH neurons during the day171. GnRH neurons have
endogenous circadian rhythms with functional clock proteins202,203. Disruption in the molecular
circadian clock results in disrupted circadian rhythm of GnRH secretion204.
1.3 Estrogens and Obesity in Women and Mice
Premenopausal women are less susceptible to the detrimental effects of obesity as
compared to men205,206. Depletion of the ovarian oocytes occurs during menopause and results
in low circulating levels of progesterone and estrogen. This causes insomnia, osteoporosis, hot
flashes, and increased risk of obesity comorbidities such as metabolic syndrome and
cardiovascular disease207-211. The protection in premenopausal women has been correlated to
less visceral/abdominal fat accumulation compared to men or postmenopausal women212.
Young women store fat subcutaneously and this correlates with improved insulin sensitivity,
glucose regulation, and fewer pro-inflammatory markers in young women as compared to
men213. Subcutaneous fat is thought to be protective since this fat type has abundant leptin, a
hormone released from fat cells that increases the feeling of satiety214-216. Subcutaneous fat cells
are also more efficient in lipogenesis and reuptake of free fatty acids than visceral fat cells217.
After menopause, fat distribution in the female body shifts from primarily subcutaneous to
visceral fat deposition, leading to increased visceral fat deposition around the waist211,218-221.
Hormone replacement therapy (HRT) is used to treat menopausal symptoms222. HRT is when
estrogens is given with or without progestin223,224. Studies show that HRT reduces visceral
adiposity in postmenopausal women210,224. Several studies have also shown that risk of
cardiovascular disease is reduced in postmenopausal women by estrogen treatment if the
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treatment is started during perimenopause225-228. HRT for perimenopausal women could
therefore be helpful to maintain good health post-menopause224.
High-fat diet-induced obesity has been well studied in rodents. Male C57BL/6J mice
have been used as a rodent model of diet-induced obesity (DIO) since they become obese and
have impaired glucose homeostasis when fed high-fat diets (that typically contain lard as the fat
source)229. In contrast, gonadally-intact female C57BL/6J mice are resistant to DIO when fed
HFD230-233. Intact female C57BL/6J mice fed HFD do not have visceral fat accumulation and are
glucose tolerant and insulin sensitive231,232,234. Therefore, there is a sex difference in disposition
to HFD-induced weight gain in C57BL/6J mice. Studying the effects of HFD on obesity and
metabolism in rodents can be useful in further understanding differences in obesity between
men and women.
Estrogen also regulates adiposity in rodents by increasing subcutaneous adipose and
reducing visceral adipocyte size232,235. Smaller adipocyte size is correlated with increased
lipogenesis and insulin sensitivity236. It has also been observed that estrogens treatment reduces
inflammatory responses in visceral fat237. In ovariectomized females and in males, the size of
abdominal adipocytes is larger compared to gonadally-intact females during LFD and HFD
feeding232. Ovariectomy causes glucose intolerance, hyperinsulinemia, and leptin resistance232.
Ovariectomy therefore causes female rodents to lose protection against the detrimental effects
of obesity. Estradiol treatment restores the protective functions of estrogen to ovariectomized
female mice232,238.
1.3.1. ERα regulates obesity and metabolism in mice
Whole-body ERα KO male and female mice have increased adipose tissue which is
mainly visceral fat239. Studies carried out on ERα KO mice fed chow showed that ERα is
necessary to prevent weight gain and adipocyte accumulation in the liver239,240. Reduced GLUT4
levels in muscles of ERα KO mice have been associated with the insulin resistant phenotype of
these mice241. ERα is highly expressed in parts of the brain associated with regulating energy91,92.
Estrogen signals via ERα to increase satiety via leptin signaling and improves energy
expenditure. ERα KO mice therefore have reduced energy expenditure and increased energy
intake239. A previous study also showed that wheel-running activity is significantly reduced in
ERα KO mice even in the presence of circulating estrogens242. Taken together this indicates that
estrogen signaling via ERα is involved in regulating metabolism in mice.
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The ERα-selective ligand propyl pyrazole triol (PPT) has 400-fold selectivity for ERα
compared to ERβ243,244. Treating mice with PPT increased uterine weight, reduced food intake
and body weight/adiposity, and improved glucose tolerance and insulin sensitivity245-247. As
expected, PPT had no effect on metabolism or improving obesity in ERα KO mice, but it
improved glucose tolerance and insulin sensitivity in ob/ob mice246. Selective activation of ERα
with PPT has been shown to increase activity levels in mice by increasing the amplitude of wheel
running activity and consolidating activity to the nighttime248.
Tissue-specific ERα KO mice have also been used to study the roles of ERα in regulating
metabolic parameters. Liver-specific ERα KO (LERKO) mice were generated by crossing floxed
ERα KO mice with Albumin-Cre mice. LERKO male mice were hyperglycemic and had increased
liver lipid deposits and triglyceride levels249. Male and female LERKO mice, however, had body
weights and insulin sensitivity similar to wild-type mice250. Neural-specific ERα KO mice, such as
Nestin-Cre ERα KO mice, which have ERα knocked out in all cells of neural and glial origin, have
an obesity phenotype with excess adiposity, increased food intake, and reduced activity on
chow diet251. ERα can also be knocked out in hypothalamic regions such as the ventromedial
hypothalamic nucleus (VMH) and pro-opiomelanocortin (POMC) neurons251. These
hypothalamic-ERα KO mice have increased food consumption and adiposity compared to wildtypes251.

1.3.2. The role of ERβ in regulating obesity and metabolism.
ERβ KO male mice fed chow do not become obese or have increased adiposity252. ERβ
KO mice on chow diet have normal glucose and insulin regulation112. However, ERβ has been
shown to be involved in regulation of diet-induced obesity and metabolism. When fed HFD,
compared to WT mice, male ERβ KO mice became obese but not insulin resistant and glucose
intolerant253. ERβ seems to be required for blood glucose regulation but functions to antagonize
the effects of ERα 239-241. , Male and female mice treated with the ERβ-selective ligand, β-LGND,
maintained a healthy weight, reduced cholesterol, improved glucose homeostasis and
prevented adipose accumulation during HFD feeding254. These studies indicate that the estrogen
anti-obesity effect via ERβ is made obvious during a HFD diet-induced obesity paradigm. The ERβ
agonist diarylpropionitrile (DPN), which is 70-fold more selective for ERβ than ERα, has no effect
on uterine weight as opposed to E2 or ERα244,245,255. DPN had no effect on food intake or body
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weight in rats fed a normal diet256,257. Selective activation of ERβ with DPN advanced the time of
activity onset and delayed the phase of activity248.
ERα/β double knockout (DERKO) mice have both ERα and ERβ knocked out globally.
DERKO mice have smaller sized uteri just like ERα KO mice161. DERKO mice become obese and
have increased adiposity just like ERα mice161,252. DERKO mice also have increased serum
cholesterol and LDL252. Most of the metabolic phenotypes of DERKO mice are mediated by ERα
loss since the phenotypes are similar to what is seen in ERα KO mice.
1.3.3. The role of GPER in regulating obesity and metabolism
GPER1 KO mice have been generated using several different targeted gene deletion
approaches258-260, including disruption of the GPER1 coding region using neo cassette insertion
or removal of an exon by Cre-loxP115. These different models have not been extensively studied
and some controversies exist about their metabolic phenotypes260-263. However, there is a
consensus that homozygous GPER1 KO mice generated by all methods are fertile and females
have normal uteri115,259,262.
Studies have shown that knock out of GPER1 causes metabolic dysfunction. Female
GPER1 KO mice are insulin-resistant, glucose intolerant, and have reduced energy expenditure,
but do not become obese or have increased adipose accumulation263-265. When female GPER1
KO mice were ovariectomized, they became obese, had increased adiposity, and had atrophied
uteri like ovariectomized wild-type mice265,266. The same studies showed that female GPER1 KO
mice responded positively to estradiol treatment just like wild-type C57BL/6J mice. GPER1 KO
mice also have macrophage accumulation and quickly develop atherosclerosis when fed high-fat
diet267,268.
1.3.4. The role of Gαq-mER in regulating obesity and metabolism
Gαq-coupled membrane ER (Gq-mER) is a recently discovered GPCR. This ER is
expressed on POMC neurons and activates rapid E2 signaling via PKC/PKA117,118. STX, a selective
activator of Gq-mER, has been shown to activate POMC neurons to inhibit orexigenic
neuropeptide Y (NPY) neurons and agouti-related peptide (AgRP) neurons in ERα-KO and ERβKO and GPER-KO mice117,269. Gq-mER plays a role in controlling energy homeostasis by reducing
food intake and visceral fat accumulation even after OVX117,270.
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1.4 Regulation of Feeding in Female Mice
Several hormones and peptides produced in the brain, fat cells, gastrointestinal tract,
and pancreas are involved in the control of appetite and energy homeostasis. These circulating
hormones/peptides maintain homeostasis of energy balance. These substances have specific
receptors in target tissues.
1.4.1. Neuroendocrine control of feeding
The hypothalamus is important for the regulation of energy homeostasis. Lesions of the
ventromedial hypothalamus (VMH) lead to hyperphagia, reduced activity, and increased
adiposity271,272. VMH-lesioned rats parabiosed to VMH-intact rats remained obese and
hyperphagic while the intact parabiosed rats became anorexic273. This indicates that satiety
factors (such as leptin) acted on the VMH of the intact rat, despite being elevated in both rats.
Lesions to the lateral hypothalamus (LHA) on the other hand lead to aphagia and
anorexia274.Thus, an intact VMH is needed for proper function of anorexigenic peptides (needed
to sense satiety) while an intact LHA is needed for proper function of orexigenic peptides
(functions to stimulate hunger). The orexigenic melanin-concentrating hormone (MCH) and
orexins (A and B) are located in the LHA275. They are neuropeptides that have been found to be
involved in energy homeostasis. MCH deficient mice have an increased metabolic rate and eat
less resulting in lower body weight276. MCH expression increases in both fasted and ob/ob mice
rodents275,277. In rodents, orexin levels have been shown to also increase with ghrelin
administration and fasting, while leptin and feeding reduces its levels278,279
The arcuate nucleus of the hypothalamus (ARC) plays a very important role in body
weight regulation and energy homeostasis. The ARC is located near the median eminence which
has an incomplete blood-brain barrier (BBB) thus making blood-borne endocrine hormones
readily available to the ARC280,281. The ARC contains several neuronal populations that have
neuroendocrine functions, and it expresses receptors for hormonal peptides, such as leptin and
insulin, gonadal steroids, and even glucose, and thus acts as a central integration site281,282 (Fig.
1.9). Anorexigenic neuropeptides, proopiomelanocortin(POMC), which is the precursor of α
melanocyte-stimulating hormone (α-MSH, and cocaine- and amphetamine-regulated transcript
(CART), alongside orexigenic neuropeptides NPY and AgRP, are co-expressed in the ARC283 (Fig.
1.9). Both POMC/CART neurons and NPY/AgRP neurons project to the melanocortin 4 receptor
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(MC4R) expressing neurons. α-MSH stimulates the MC4R to control energy balance by reducing
food intake and increasing energy expenditure283. Fasting decreases POMC (and therefore αMSH expression) levels while fasting or ghrelin increases NPY/AgRP expression levels284,285.
Intracerebroventricular (ICV) administration of leptin and insulin in rats increases POMC
expression while reducing both NPY and AgRP expression in the ARC and are
anorexigenic288. POMC and NPY neural projections are sent to the LHA, which acts to

286,287

integrate the various incoming stimuli (Fig. 1.9).
The nucleus of the tractus solitarius (NTS) in the brainstem receives endocrine
stimulation from the GI tract via vagus afferent neurons289,290. The vagus nerve is known to
innervate most metabolic tissues291. The vagus nerve is known to send satiety signals to various
parts of the body (gut, brain, etc.). ERα expression in the vagus nerve also changes across the
estrous cycle292. LepR have been shown to be co-localized with the subset of POMC neurons in
the NTS of both rat and mice showing other possible areas where leptin could exert its energy
expenditure contol293.
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Figure 1. 9. Schematic diagram of the brain regions that control food intake and energy
expenditure.
The hypothalamus receives hormonal and neural signals and functions to maintain energy
homeostasis. Leptin and Insulin can activate POMC neurons or repress NPY neuronal activity
in the ARC to reduce food intake and increase energy expenditure. Ghrelin can also activate
NPY neurons to stimulate hunger and reduce activity. These controls are done via the
melanocortin pathway in the PVN and LHA of the hypothalamus.
1.4.2. Hormones secreted from peripheral tissues that affect feeding
Leptin regulates energy homeostasis by inhibiting hunger and reducing fat stores. Leptin
is released from adipocytes in the white adipose tissue. Plasma leptin levels increase with
feeding and decrease with starvation. Leptin levels also increase with increased adiposity294.
Leptin administration is only effective in reducing adiposity and food intake in non-obese and
leptin-deficient subjects295. This is because obese individuals have a higher leptin level already
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and their lack of response to circulating leptin results from leptin resistance. Parabiosis studies
using obese (ob/ob) and diabetic (db/db) mice have shown that while ob/ob mice lack the
satiety peptide (leptin), db/db mice (with mutated leptin receptor) had excess leptin but their
cells were unable to respond295. Leptin administered into the CNS of ob/ob mice was sufficient
to reverse the obesity phenotype295. Leptin receptors are found in hypothalamus in the ARC and
VMH (Fig. 1.9). Leptin receptors are also present in other parts of the CNS, specifically in the
steroidogenic factor 1 (SF1) cells in the VMH296,297. When the leptin receptor is knocked out in
SF1 neurons, the mice become obese on low-fat and HFD. Both male and female SF1/LepR-KO
mice develop DIO as a result of hyperphagia and reduced energy expenditure297. Obesity and
increased adiposity phenotype of SF1 and LepR-KO mice is compounded by the deletions of
LepR in POMC and SF1 neurons (SF1/LepR-KO) 297.
Cholecystokinin (CCK) is a peptide hormone involved in fat and protein digestion. It acts
as a satiety hormone and its plasma level rises with food availability (especially by a fat and
protein-rich meal than a carbohydrate diet). It is produced in a specialized group of cells,
enteroendocrine cells, in the duodenum. It acts by contracting the gall bladder and stimulating
secretion of pancreatic enzymes and by slowing gastric emptying to inhibit food intake298-300.
CCK binds the G-protein-coupled CCK-1 and CCK-2 receptors found in the GI tract, peripheral
vagal afferent terminals, and brain301. CCK-1-KO rats have hyperphagia and obesity302,303. A
noteworthy site of CCK action is the NTS in the brainstem where CCK binds its receptor and
activates POMC neurons which then signals via the MC4Rs to increase satiety in mice304.
Although CCK administration reduces food intake per meal in rats, meal frequency increases and
thus body weight is not affected305.
Peptide YY (PYY) is secreted from the L cells of the GI tract with a lower level during
periods of fasting and increasing concentration with fat and protein-rich meals (as compared to
carb-rich meals)306. It acts to reduce food intake and decrease gut motility/gastric emptying
when administered peripherally307,308. However, when injected in the ICV it acts as an orexigenic
hormone in rats309,310. PYY acts by its receptors Y1, Y2 and Y5. Y2 has been shown to repress the
orexigenic NPY neurons while Y1 and Y5 receptors seem to be involved in the orexigenic effect
of PYY311. Administration of PYY reduces food intake and weight gain in rats via the Y2
receptor312. The mechanism of PYY food-intake control is still being investigated.
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Pancreatic polypeptide (PP) is synthesized in the GI and pancreas and its circulating
levels increase with food intake. PP functions to inhibit gastric emptying (increase satiety)313,314.
In rodents, PP binds with highest affinity to the Y4 receptor compared to other Y family receptor
subtypes315. The vagus nerve has been shown to be a key component of PP anorexic action as PP
does not reduce food intake in vagotomized mice314. Interestingly ob/ob mice have very few PPexpressing cells in the pancreas and continuous administration of PP not only reduces both food
intake and body weight but also improve blood glucose and lipid levels in these mice314,316. Like
PYY, there is an effect of administration site on PP effect with PP acting as an orexigenic peptide
when administered in the ICV but acting as an anorexigenic peptide when administered
peripherally317,318.
Glucagon-like peptide-1 (GLP-1) is cleaved from pro-glucagon and released by L cells of
the GI tract. It is also present in the parts of the brain associated with appetite control such as
the ARC, dorsomedial hypothalamus (DMH) and paraventricular nucleus (PVN)319-321. It functions
to inhibit gastric secretion and thus decrease glucagon levels and reduce gastric emptying322.
GLP-1 is known to stimulate insulin release by binding to its G-protein coupled receptor (GLP1-R)
on the β pancreatic cells and increasing insulin synthesis323,324. Thus GLP-1 plays a huge role in
the incretin effect which allows for increased insulin secretion in the presence of oral glucose
administration as opposed to when administered intravenously (IV)325. Mice lacking GLP1-R
thereby become glucose intolerant and are hyperglycemic326. Both the intracerebroventricular
(icv) and peripheral administration of GLP-1 in rodents is anorexigenic and inhibits weight
gain326-328.
Oxyntomodulin (OXM) is also cleaved from pro-glucagon and released by L-cells of the
GI tract. Itis released in response to food availability. Like GLP-1, it also functions to reduce
gastric secretions and emptying329,330. OXM binds GLP1-R331 and is present in the ARC329. OXM
injected via the central or peripheral route has anorexic effects329,332.
Ghrelin is produced in the stomach in response to hunger as the circulating level
increases with fasting333. Ghrelin functions to increase gastric secretions and motility334. It is
unique in that it increases appetite and body weight thereby acting as an orexigenic
peptide333,334. Ghrelin has been shown to not only increase NPY expression in the ARC335, its
expression level is decreased by insulin administration and increased in ob/ob mice336. Ghrelin
binds to the growth hormone secretagogue receptor (GHS-R) thus it also stimulates the release
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of growth hormone, and this receptor is also present in the ARC335(Fig. 1.9). Studies have also
shown that both Ghrelin-KO and GHS-RKO mice are protected from DIO337,338. Additionally, while
ghrelin-KO mice also have reduced expression of fat storage peptides like lipoprotein lipase and
fatty acid synthase, CNS administration of ghrelin increases fat storage and decreases lipid
oxidation339.
Motilin is released by GI cells in response to fasting. It stimulates gastric enzyme
secretion to increase hunger340. Both the central and peripheral route of motilin administration
have orexigenic action in rodents340-342. Somatostatin is synthesized by the D-cells of the GI tract
and the pancreas. Also known as the somatotrophin release inhibitory factor (SRIF), it acts as an
antisecretory hormone to inhibit the gastric secretion and emptying343,344.
Glucagon is cleaved from pro-glucagon and released by the α cells of the pancreas in
response to hypoglycemia. Glucagon functions in opposition to insulin in that it helps to increase
blood glucose. It does this by stimulating the liver’s breakdown of stored glycogen and activating
gluconeogenesis pathway in the liver345,346.
Insulin is secreted from β cells of pancreatic islets and released acutely in response to
increased blood glucose and chronically in response to fat mass. Insulin acts to enhance glucose
uptake into cells and its metabolism. Insulin acts by binding a family of tyrosine kinases growth
factor receptor insulin receptor (InsR), type 1 insulin-like growth factor (IGF) receptor (Igf1r)347.
Insulin regulates food intake and adiposity by reducing food intake when insulin levels are high.
It is thus important for energy balance282,348. InsR-KO mice have been shown to not only be
insulin resistant and hyperglycemic, they also have reduced growth349,350. Rats whose CNS InsR
has been selectively reduced with antisense oligodeoxynucleotide quickly developed
hyperphagia and increased fat mass351. Rats with selective InsR reduction in the hypothalamus
specifically had reduced ARC InsR leading to increased NPY/Agrp peptides351(Fig. 1.9). InsR role
in energy homeostasis does not seem to be mediated via the POMC neurons as InsR deletion in
POMC were not hyperphagic or obese352,353. Female (but not male mice) mice with defective
InsR in the CNS were both hyperphagic and obese suggesting a sex difference in the role of
insulin.
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1.4.4. Estrogenic control of feeding
Estrogens has been shown to decrease food intake and increase energy expenditure in
female rats and mice235,354. Ovariectomized female mice consume more food on both on LFD
and HFD as compared to intact females, and they become obese231,232,355. Aromatase is an
enzyme required for the conversion of testosterone to estradiol 185,227. Compared to wild-type
mice, ArKO mice do not consume more calories but they have reduced activity and develop
obesity and accumulate abdominal fat356. They also have elevated serum insulin, leptin and
cholesterol while blood glucose levels remained comparable to wild-types356.
Estrogenic regulation of food intake, fat deposition, and energy expenditure is carried
out by POMC neurons that express leptin and insulin receptors357 (Fig. 1.9). Both ERα251 and GqmER117,269 are co-expressed with POMC neurons. Estrogens can stimulate POMC neurons and
inhibit NPY/AgRP neurons. Female mice with ERα knocked out in POMC neurons become
hyperphagic and develop DIO251. ERα is also expressed on SF1 neurons of the VMH. Female mice
with ERα knocked out in SF1 neurons develop DIO, glucose intolerance, and have reduced
energy expenditure358.

1.5 Estrogen regulation of daily and circadian rhythms
Estrogens interaction with the circadian system in regulating reproductive cycles was
discussed above. This section will describe estrogen regulation of locomotor activity rhythms
and molecular circadian rhythms in tissues.
1.5.2 Estrogen regulation of locomotor activity rhythms
Natural variations in levels of estrogens across the estrous cycle influence circadian
activity rhythms in female rodents359. The phase angle between lights off and activity onset is
smaller when circulating estrogen levels are high in intact hamsters compared to ovariectomized
hamsters360. This means that intact female mice become active earlier in the day when they are
in estrus as compared to when they are in dietestrus359. This phenomenon is termed scalloping
and occurs cyclically in intact female rodents during the estrus cycle359-362. This scalloped pattern
is seen in a 4–5-day pattern in intact hamsters and is consistent with the estrous cycle but is lost
after ovariectomy.
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There are sex differences in activity levels in rodents. Female Wistar rats and C57Bl/6J
mice have more wheel-running activity than males on ad libitum or time-restricted diets363,364.
This sex difference results from circulating estrogens365. Ovariectomy also reduces activity levels
in females and estradiol treatment brought activity levels back up. Estradiol replacement to
ovariectomized mice also consolidated their locomotor activity to the night242,355,366. Removal of
circulating estrogen in mice by ovariectomy also shortened the free-running period and delayed
activity onset in constant darkness359. Ovariectomy also reduces activity levels in females and
estradiol treatment brought activity levels back up. Estradiol replacement to ovariectomized
mice also consolidated their locomotor activity to the night242,355,366.
Activation of ERα by estrogens or the ERα agonist, PPT, has been shown to be
responsible for increased wheel-running activity and the consolidation of this activity to nighttime in mice248. Activation of ERβ by estrogens or the ERβ agonist, DPN, delayed the wheelrunning activity phase and advanced activity onset after light out248.
1.5.3 Estrogen regulation of molecular circadian rhythms
Several studies have also indicated that estrogen influences molecular circadian rhythms
in tissues in mammals. In vitro estradiol treatment shortened the period of PER2::LUC rhythms
in uterus tissue explants, but did not affect the SCN and pituitary367.
So how exactly do ERα and the circadian genes interact on a molecular level? The Per2
promoter region in humans and mice contains an ERE site368. ERα bound to the ERE in the Per2
promoter region which upregulated PER2 expression in HME cells369. Increased PER2 in the
cytoplasm did not prevent localization of ERα to the nucleus but increased the rate of ERα
proteasomal degradation368. E2 shortened the period of the PER2::LUC rhythm in uterine tissue
of ovariectomized mice but not in their SCN indicating the role of ERα-ERE mediated estrogenic
effect367. In addition, Per1 and Per2 have ERE half-sites368 which only ERα can bind to, although
at a lower level370. PER2 is also known to upregulate BMAL1 transcription371 (Fig. 1.1). Therefore,
if ERα binding the Per2 ERE (mediated by E2 signaling) was prevented, BMAL1 would be
upregulated. Specifically in the liver and ovary, Per2 and Bmal1 mRNA show diurnal rhythms and
the estrous cycle affects their expression rhythm with higher mRNA levels during diestrus
compared to proestrus372. These examples show how E2 via ERα binding to ERE sites of circadian
genes can regulate circadian gene and how ER can also be regulated in turn. Clock also has an
ERE in its promoter region and E2 action via ERα increased CLOCK expression in MCF-7 cells373.
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1.6 Aims of the current study
In this dissertation, I aimed to investigate estrogens regulation of daily rhythms
underlying obesity in female mice. I first determined if circulating estradiol is responsible for
protecting the daily metabolic rhythms in female mice from high-fat diet-induced disruption
(Chapter 2). The second aim was to investigate the effect of knocking out ERα, ERβ, or GPER in
male and female mice on the circadian organization of tissue clocks (Chapter 3). The third aim of
this study was to investigate the estrogen signaling mechanisms that protect daily metabolic
rhythms in females from disruption by high-fat feeding (Chapter 4).
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CHAPTER 2: ESTRADIOL REGULATES DAILY RHYTHMS UNDERLYING DIET-INDUCED OBESITY IN
FEMALE MICE
Oluwabukola Omotola1, Sandra Legan2, Emily Slade3, Ayooluwatomiwa Adekunle4, Julie S.
Pendergast1*
Departments of 1Biology, 2Physiology, 3Biostatistics, and 4Epidemiology
University of Kentucky, Lexington, KY
Adapted from: American Journal of Physiology-Endocrinology and Metabolism (2019). Estradiol
regulates daily rhythms underlying diet-induced obesity in female mice. doi:
10.1152/ajpendo.00365.2019
N.B: some parts of the text has been modified to match dissertation style.

Abstract
The circadian system is a critical regulator of metabolism and obesity in males, but its
role in regulating obesity in females is poorly understood. Since there are sex differences in the
development of obesity and susceptibility to obesity-related disorders, we sought to determine
the role of estrogens in regulating the circadian mechanisms underlying diet-induced obesity.
When fed high-fat diet, C57BL/6J male mice gain weight while females are resistant to dietinduced obesity. Here we demonstrate that estradiol regulates circadian rhythms in females to
confer resistance to diet-induced obesity. We found that ovariectomized females with
undetectable circulating estrogens became obese and had disrupted daily rhythms of eating
behavior and locomotor activity when fed high-fat diet. The phase of the liver molecular
circadian rhythm was also altered by high-fat diet feeding in ovariectomized mice. Estradiol
replacement in ovariectomized females fed high-fat diet rescued these behavioral and tissue
rhythms. Additionally, restoring the daily rhythm of eating behavior in ovariectomized females
with time-restricted feeding inhibited diet-induced obesity and insulin resistance. Together,
these data suggest that the circadian system is a target for treating obesity and its comorbidities
in women after menopause, when circulating levels of estrogens are too low to protect their
circadian rhythms.

Keywords: circadian, female, ovariectomy, estrogen, time-restricted feeding
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Introduction
Obesity is arguably the greatest threat to the health and financial well-being of people
living in Westernized countries. Nearly 40% of adults in America are obese205. Obesity
comorbidities such as heart disease and diabetes account for 25% of deaths in the U.S.
annually374. Because of the enormous costs of obesity, massive research efforts have focused on
understanding the basic mechanisms of obesity and related disorders with the hope of
identifying therapeutics. A well-established experimental model of obesity in rodents is to
increase adiposity by feeding high-fat diet229. This so-called diet-induced obesity is relevant to
understanding human physiology since consumption of a high-fat diet, along with decreased
physical activity, are well-documented causes of obesity in the U.S.375
Most studies that have investigated the mechanisms of diet-induced obesity have used
male mice. Male C57BL/6 mice are more susceptible to high-fat diet-induced obesity,
hyperinsulinemia, and glucose intolerance compared to females230-233. However, when females
are ovariectomized, they become susceptible to diet-induced obesity, similar to males230-233. The
resistance to diet-induced obesity is, in large part, due to circulating estrogens since estradiol
replacement in ovariectomized females restores resistance to diet-induced obesity and the
related pathology232,376-378.
Men and women also differ in their susceptibility to obesity-related disorders. Young,
premenopausal women have lower incidence of cardiometabolic disease compared to agematched men379,380. However, after menopause and the decline in circulating estrogens, the risk
of metabolic syndrome and cardiovascular disease increases dramatically381. When women take
estrogens (sometimes in combination with progesterone) during and after menopause
(beginning within 10 years of menopause), the risk of obesity, diabetes, and cardiovascular
disease is markedly lower compared to postmenopausal women without hormone replacement
therapy382-386. Therefore, as in mice, circulating estrogens have been implicated as protective
against metabolic dysfunction in women.
Disruption of circadian rhythms has also been implicated as a risk factor for obesity and
cardiometabolic dysfunction387. We and others have shown that daily rhythms of food intake
and circulating metabolic hormones, as well as circadian rhythms in metabolic tissues (e.g. liver)
are altered when male C57BL/6J mice are fed high-fat diet388-390. In contrast, we showed that
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daily metabolic rhythms in female C57BL/6J mice are not altered during high-fat feeding230.
Notably, these females are also resistant to diet-induced obesity. These data raise the intriguing
possibility that the circadian system plays a key role in protecting females from metabolic
dysfunction. In this study, we sought to determine whether estradiol regulates the circadian
system to inhibit diet-induced obesity in female mice.

Materials and Methods
Animals
C57BL/6J female mice were generated for these experiments in our animal facility in
12L:12D. Heterozygous C57BL/6J PERIOD2::LUCIFERASE (N26 to N29; backcrossed to C57BL/6J
mice purchased from The Jackson Laboratory) were crossed with wild-type C57BL/6J mice (The
Jackson Laboratory stock# 000664) to generate the female heterozygous PER2::LUC and wildtype mice that were used. Breeders and offspring were housed in 12L:12D and fed standard
rodent diet (Teklad 2918; 18% kcal fat; 3.1 kcal/g metabolizable energy) and water ad libitum.
Pups were weaned and group-housed (2-5 same-sex mice/cage) at 21 days old. Tail snips were
collected from pups at weaning and genotyped by measuring luminescence with a luminometer.
All procedures were submitted to and approved by the Institutional Animal Care and Use
Committee at the University of Kentucky (protocol number 2015-2211).
Experimental Protocols
Experiment I: Effects of estradiol on mediating the effects of high-fat diet consumption
on daily rhythms
At 6 weeks old, females were ovariectomized and implanted with Silastic tubing
containing either vehicle (n=26) or E2 (n=27) and single-housed with ad libitum rodent diet (18%
kcal fat, Teklad 2918) for 1 week. Some mice were heterozygous PER2::LUC (n=11/group) and
the remainder were wild-type. At 7 weeks old, mice were placed in cages
(33 cm × 17 cm × 14 cm) with locked running wheels (running wheels were present but could
not rotate; wheel-running activity was never measured in this study) in light-tight boxes in
12L:12D (250-350 lux, white LEDs). All mice were fed low-fat diet (10% kcal fat; 3.85 kcal/g,
Research Diets D12450K) for the first week and then high-fat diet (45% kcal fat; 4.73 kcal/g,
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Research Diets D01060502) for one week. We used 45% kcal high-fat diet because this is
equivalent to the amount of fat consumed (as a percentage of total dietary energy
consumption) by humans in the U.S.391. Body weight and food consumption were measured
weekly between during the 3h before lights out [Zeitgeber time (ZT) 9-12, where ZT 0 is lights on
and ZT12 is lights off; measurements were taken before the diets were switched]. Energy intake
(kcal) was calculated from grams of food consumed during each week. At 9 weeks old, some
females were fasted from ZT3 to ZT10 and killed at ZT10 by cervical dislocation and
decapitation. Fasting blood glucose was measured with a glucometer (Accu-Chek Aviva) and
body composition (EchoMRI-100) was determined. At 9 weeks old, other females that were
heterozygous for PER2::LUC were not fasted and tissues were collected to analyze
bioluminescence rhythms in tissues (see method below).
Experiment II: Effects of time-restricted feeding on diet-induced obesity and
metabolism in ovariectomized mice
Females were ovariectomized at 6 weeks old (n=35) and single-housed with ad libitum
rodent diet (18% kcal fat, Teklad 2918) for 1 week. Some mice were heterozygous PER2::LUC
(n=5-6/group) and the remainder were wild-type. At 7 weeks old, mice were single-housed in
cages with locked running wheels in 12L:12D and fed rodent diet (18% kcal fat, Teklad 2918) ad
libitum for 1 week. At 8 weeks old, females were randomized to be fed high-fat diet ad libitum
or only during the 12-h dark phase (time-restricted feeding). In the time-restricted feeding
group, food was provided and removed manually. To ensure that all mice were exposed to
similar conditions, both groups were housed in the same light-tight box and food was weighed
at ZT0 and ZT12 every day. Body weight was measured weekly and body composition was
measured at 14 weeks old. At 15 weeks old, glycemic control was determined by oral glucose
tolerance tests (OGTT). Briefly, mice were fasted from ZT0-6 and fasting blood glucose was
measured. At ZT6, 2g/kg dextrose (in PBS) was administered by oral gavage and blood glucose
was measured after 15, 30, 60, and 120 minutes. After the OGTTs, mice were maintained in
their feeding conditions for 1 week. At 16 weeks old, wild-type females were fasted from ZT0-8
and killed by cervical dislocation and decapitation at ZT8 and blood glucose (Accu-Chek Aviva),
plasma insulin (ELISA, Crystal Chem), plasma cholesterol (Wako Pure Chemical Industries), and
plasma triglycerides (Wako Pure Chemical Industries) were determined. HOMA-IR was
calculated as [fasting plasma insulin (mU/L) x fasting blood glucose (mg/dL)]/405392.
37

Bioluminescence was measured from tissues explanted from heterozygous PER2::LUC females at
16 weeks old.
Ovariectomy surgeries
Females were deeply anesthetized with inhaled isoflurane and given 5-10 mg/kg
subcutaneous ketofen analgesic (Henry Schein) pre-operatively. Briefly, a midline dorsal skin
incision was made, followed by two lateral incisions on the peritoneal wall. PGA ligatures were
tied around the oviducts just proximal to the ovaries and the ovaries were then removed.
Peritoneal incisions were closed with simple interrupted stitches and the skin incision was
closed with wound clips. Mice were implanted with Silastic tubing (Dow-Corning, inner
diameter: 1.98mm; outer diameter:3.18mm; length of tubing: 18mm; length of plugs: 5mm
each) containing either sesame oil (Sigma-Aldrich) or 0.625 μg/capsule (25µl of 25µg/mL,
equivalent to 0.8 μg·kg−1·day−1) of 17-β estradiol (E2, Sigma-Aldrich) dissolved in sesame oil as
previously described171. Tubing was implanted subcutaneously in a pocket made in the dorsal
aspect of the neck during the same surgical procedure. Previous studies have shown that Silastic
tubing containing this concentration of E2 provides a physiological dose of estrogen (5-35
pg/mL) for up to 30 days238,393. After surgery, mice were single-housed and fed rodent diet (18%
kcal fat, Teklad 2918) ad libitum for 1 week. Post-operative analgesic (5-10 mg/kg ketofen s.c.)
was administered 24 h and 48 h after surgery and wound clips were removed 7 days after
surgery. The absence or presence of circulating estrogen was verified by weighing uteri at the
end of experiments. Uterine weight is a reliable bioassay for circulating E2 levels. The levels
attained by our implants were similar to those in intact female mice (Fig. S1).
Eating Behavior Rhythm Recording and Analysis
Eating behavior was continuously recorded using infrared cameras (HD 48Led 940nm
Outdoor CMOS 800TVL IR-Cut Dome camera waterproof IF CCTV) connected to an MPX HD
1080p Security System DVR (Lorex). Videos were viewed and analyzed in 1 min-bins as
previously described389. Individual days of eating behavior data were plotted in circular
histograms in 10-min bins (Oriana 4.02; Kovach Computing Services, Wales, UK).
Locomotor Activity Rhythm Recording and Analysis
Locomotor activity was continuously monitored using passive infrared sensors (Adafruit)
interfaced to a computer with ClockLab Acquisition software (Actimetrics, Wilmette, IL).
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Actograms of locomotor activity (6-min bins; scaled setting: 7 Max) were plotted using Clocklab.
In Experiment I, average daily locomotor activity (6-min bins) during 6 days of low-fat diet
feeding and 6 days of high-fat diet feeding were used to generate activity profiles. In Experiment
II, locomotor activity (6-min bins) during 6 weeks of high-fat diet feeding were used to generate
activity profiles. The individual activity profiles of each mouse were analyzed by the cosinor
method to determine the amplitude (half of the peak-to-trough value), mesor (Midline Statistic
of Rhythm or rhythm-adjusted mean), and acrophase (the timing of the peak of the rhythm) of
the daily rhythms of activity (Actimetrics).
Bioluminescence Recording and Analysis
Heterozygous PER2::LUC female mice were killed by cervical dislocation and
decapitation within 1.5h before lights out (ZT10.5-12). Coronal SCN slices (300µm) and explants
of aorta, kidney, liver, lung, pituitary, spleen, and white adipose tissue were dissected and
cultured to measure bioluminescence as previously described66,394. Tissue bioluminescence was
measured in 10-min intervals using the LumiCycle apparatus (Actimetrics). Data were smoothed
(30-min) and detrended using LumiCycle Analysis software (Actimetrics). The phases (acrophase)
of bioluminescence expression were determined between 12-36h in culture using ClockLab
Analysis software (Actimetrics).
Statistical Analysis
Mixed measures ANOVA models were used to analyze the effect of ovariectomy with or
without E2 replacement on body weight and the effect of time-restricted feeding on body
weight, glucose tolerance, and caloric intake (SPSS Statistics 25; post-hoc t-tests adjusted for
multiple comparisons). Independent Student’s t-tests (two-tailed) were used to compare
adiposity, fasting blood glucose, energy intake, and total activity. The phases of tissue PER2:LUC
rhythms were analyzed by one-way ANOVA followed by post-hoc Fisher tests. in Experiment I,
and the area under the curve for glucose tolerance tests, and total energy intake and activity in
Experiment II (OriginPro). Paired Student’s t-tests (two-tailed) were used to compare the
amplitudes and phases of eating behavior and locomotor activity rhythms during low-fat diet
and high-fat diet feeding (OriginPro). Circular data were analyzed using Oriana 4.0. The mean
vector of each day of eating behavior data for an individual mouse was determined by Rayleigh’s
uniformity test to determine if eating events were non-uniformly distributed (Oriana). We
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defined the amplitude and phase of the eating behavior rhythm as the length (r) and angle (µ),
respectively, of the mean vector. Eating behavior was defined as arrhythmic when Rayleigh’s
uniformity test p>0.05 (indicating that eating events were uniformly distributed). In this case,
the amplitude of the eating rhythm was designated as 0 and there was no value for phase (these
mice were not included in the mean values for phase). Significance was ascribed at p < 0.05.

Results
Estradiol replacement inhibits diet-induced obesity in ovariectomized mice
We and others have shown that female C57BL/6J mice are resistant to diet-induced
obesity230-233. We first investigated the role of estrogens in mediating resistance to diet-induced
obesity in females. We measured body weight (Fig. 2.1A) and adiposity (Fig. 2.1B) in female
C57BL/6J mice that were ovariectomized and implanted with Silastic tubing containing either
vehicle or 17-β estradiol (E2). We confirmed the E2 implants delivered physiological doses of E2
during our experiment because intact (not ovariectomized) females and E2-implanted females
had similar uterine weights (Fig. S1). The mice were fed low-fat diets for 2 weeks (Fig. 2.1A: 6-8
weeks old) and then high-fat diet for 1 week (Fig. 2.1A: 8-9 weeks old; Fig. S2A). Ovariectomized
mice with no circulating E2 gained weight at higher rate over the study period than
ovariectomized females with E2 treatment (Fig. 2.1A; mixed measures ANOVA time x treatment
p<0.001). Ovariectomized females also had increased adiposity at 9 weeks old (Fig. 2.1B;
p<0.001), consumed more calories (Fig. 2.1C; p<0.001), and were less active (Fig. 2.1D; p<0.001)
during 1 week of high-fat diet feeding compared to ovariectomized females with circulating E2.
Fasting blood glucose measured at 9 weeks old did not significantly differ between the groups
(Fig. 2.1E; p= 0.31).
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Figure 2. 1. Estradiol replacement inhibits diet-induced obesity in ovariectomized (OVX)
mice.
Female C57BL/6J mice were ovariectomized and implanted with tubing containing either
vehicle (red) or 17β-estradiol (E2: blue). Body weights (A) of mice fed low-fat diet (6-8 weeks
old) for 2 weeks and then 45% high-fat diet for 1 week (8-9weeks old; arrow indicates that
high-fat diet was initiated after body weight was collected at 8 weeks; n=26-27/group). Body
composition (B) was measured at 9 weeks old (n=9-11/group). Energy intake (C: kcal/week)
and total activity (D) were measured during 1 week of high-fat diet feeding (8-9 weeks old;
n=26-27/group). Fasting blood glucose was measured at 9 weeks old (n =8-10/group). Data
are mean ±SEM.*p<0.01.
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Estradiol inhibits disruption of the daily rhythm of eating behavior by high-fat diet
feeding
We previously showed that female C57BL/6J mice, in contrast to males, had highamplitude daily rhythms of eating behavior during high-fat feeding230,389. Ovariectomy abolished
this sex difference, suggesting that estrogens could protect female rhythms from disruption by
high-fat diet feeding230. Therefore, we next determined whether replacing ovary-intact levels of
circulating estrogen regulated the effect of high-fat diet consumption on the eating behavior
rhythm in female mice. We treated ovariectomized females with implants containing either
vehicle or E2 and measured daily rhythms of eating behavior during low-fat diet and high-fat
diet feeding (Fig. 2.2, S3, S4, S5). Ovariectomized mice treated with vehicle had eating behavior
rhythms that peaked during the dark phase during low-fat diet feeding (Fig. 2.2 A,C,H). The
amplitude of the eating behavior rhythm decreased (Fig. 2.2 D,G, p<0.01) and the phase of the
eating behavior rhythm advanced (Fig. 2.2 D,H, p=0.04) when the vehicle-treated
ovariectomized mice were fed high-fat diet. Overall, the effects of high-fat diet feeding on the
daily rhythm of eating behavior in ovariectomized females mimicked the effects of high-fat diet
feeding in male mice388,389. In contrast, ovariectomized females with E2 replacement maintained
high-amplitude eating behavior rhythms during low-fat diet (Fig. 2.2 B,E,I) and high-fat diet
feeding (Fig. 2.2 B,F,I). The amplitude (Fig. 2.2 F,I, p=0.49) and phase (Fig. 2.2 F,J, p=0.65) of the
eating behavior rhythm was not affected by high-fat diet feeding in ovariectomized females with
E2 replacement. These data show that E2 replacement after ovariectomy confers highamplitude eating behavior rhythms during high-fat feeding in female mice.
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Figure 2. 2. Circulating estradiol inhibits disruption of the daily rhythm of eating behavior by
high-fat diet feeding in female mice.
Females were ovariectomized and treated with vehicle (A,C,D,G,H; OVX + vehicle) or 17βestradiol (B,E,F,I,J; OVX + E2). Representative actograms of eating behavior in ovariectomized
mice treated with vehicle (A) or 17β-estradiol (B) and fed low-fat diet (LFD) for 1 week and
then high-fat diet (HFD) for 1 week (white bar is lights on and black bar is lights off; red
asterisks in A and B show when the diet was switched). Representative circular histograms (CF) and mean (±SEM) amplitudes (G,I) and phases (H,J) of eating behavior rhythms on the last
day of LFD feeding (indicated by pink arrow in A and light blue arrow in B) and last day of HFD
feeding (indicated by red arrow in A and dark blue arrow in B). Circular histogram scale: inner
circle, 5; outer circle, 10 eating events. 0-12: lights on; 12-0: lights off. The lengths and
directions of the vectors represent the amplitudes and phases of the eating behavior
rhythms, respectively. n=17/group, except H: n=14/group (3 OVX + vehicle mice had
arrhythmic eating behavior during HFD feeding and therefore had no phases). *p<0.05 vs.
LFD.
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Estradiol increases the amplitude of the daily locomotor activity rhythm during highfat diet feeding
We next examined the effects of high-fat diet feeding on the daily rhythm of locomotor
activity in females with and without circulating E2 (Fig. 2.3, S6, S7). Ovariectomized females
treated with vehicle (Fig. 2.3 A,C) or with E2 (Fig. 2.3 B,D) had high-amplitude daily rhythms of
nocturnal activity during low-fat feeding. The amplitude (Fig. 2.3E, p=0.12) and mesor (Fig. 2.3F,
p=0.30) of the activity rhythm was not significantly affected by high-fat diet feeding in vehicletreated ovariectomized females. In contrast, the amplitude (Fig. 2.3G, p<0.001) and mesor (Fig.
2.3H, p<0.001) of the activity rhythm increased during high-fat diet feeding in ovariectomized
mice with E2 replacement. The phase of the activity rhythm was not significantly altered by
high-fat feeding in ovariectomized mice treated with vehicle (Fig. S8A, p=0.07) or E2 (Fig. S8B,
p=0.27).
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Figure 2. 3. Circulating estradiol enhances the amplitude of the daily locomotor activity
rhythm during high-fat diet feeding.
Females were ovariectomized and treated with vehicle (A,C,E,F; OVX + vehicle) or 17βestradiol (B,D,G,H; OVX + E2). Representative actograms of locomotor activity (6-min bins;
scaled max count:7), measured by passive infrared sensors, of ovariectomized females
treated with vehicle (A) or 17β-estradiol (E2, B). Mice were fed low-fat diet (LFD) for 1 week
and high-fat diet (HFD) for 1 week (red asterisk indicates when the diet was switched). Mean
(±SEM) activity profiles (C,D), amplitudes (E,G), and mesors (F,H) of locomotor activity
rhythms during LFD feeding (days 1-6) and HFD feeding (days 8-13). n=17 mice/group.
*p<0.001 vs. LFD.
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Estradiol regulates the phase of the liver circadian clock during high-fat diet feeding
We previously showed that high-fat diet feeding, compared to low-fat diet feeding,
advanced the phase of the molecular circadian clock in the livers of male, but not intact female,
C57BL/6J mice230,389,395. We next sought to determine whether circulating E2 regulates the phase
of the liver clock during high-fat diet feeding (Fig. 2.4, S9). PERIOD2 is a core component of the
molecular circadian timekeeping mechanism. We measured bioluminescence in tissues
explanted from PERIOD2::LUCIFERASE mice as a readout of the molecular clock. Tissues were
cultured from intact females or from ovariectomized mice treated with vehicle or E2 and fed
high-fat diet for 1 week. The phases of the PER2::LUC rhythms in the SCN, pituitary, kidney, lung,
aorta, spleen, and white adipose tissue (WAT) did not significantly differ between intact
females, ovariectomized females treated with vehicle, and ovariectomized females treated with
E2 (Fig. 2.4). The phase of the liver PER2::LUC rhythm was advanced ~4h in ovariectomized
females treated with vehicle compared to intact females (p<0.05) and those treated with E2
(p<0.001). Notably, the magnitude of the phase advance of the liver rhythm in ovariectomized
mice treated with vehicle and fed high-fat diet was similar to that in males fed high-fat
diet389,395. These data show that high-fat diet feeding disrupts circadian organization by
advancing the phase of the liver circadian clock in ovariectomized females and circulating E2
inhibits this disruption.
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Figure 2. 4. Circulating
estradiol prevents the phase
advance of the liver circadian
clock during high-fat feeding
in female mice.
Intact (gray) and
ovariectomized PER2::LUC
females treated with vehicle
(red) or 17β-estradiol (E2,
blue) were fed high-fat diet
for 1 week. Tissues were
cultured and bioluminescence
was measured. The mean
phases (±SEM) of the peaks of
the bioluminescence rhythms
were plotted relative to last
lights on. Light and dark is
indicated by the white and
black bar, respectively.
Number of rhythmic
samples/number of samples
cultured is shown for each
tissue. *p<0.05.

Time-restricted feeding inhibits diet-induced obesity and glucose intolerance in
ovariectomized mice
We next tested whether the disrupted eating behavior rhythm contributed to the
development of diet-induced obesity in ovariectomized mice. Beginning at 8 weeks old, singlehoused ovariectomized mice were fed high-fat diet either ad libitum or only during the 12-h
dark phase (time-restricted feeding) to correct the disrupted eating rhythm: ZT12-24; Fig. 2.5,
S2B). We found that ovariectomized mice in the time-restricted feeding condition gained weight
at a lower rate over the study period (mixed measures ANOVA time x group p=0.001; Fig. 2.5A)
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and had lower adiposity at 14 weeks old (Mann-Whitney p<0.05; Fig. 2.5B) compared to ad
libitum-fed mice. Plasma cholesterol and triglycerides were not significantly affected by timerestricted feeding (Fig. S10). Total energy intake was greater in the ad libitum-fed group
compared to the time-restricted feeding group after 3 weeks of high-fat diet feeding (Fig. 2.5C,
p<0.01, Fig. S11). Total activity levels were not significantly affected by time-restricted feeding
(Fig. 2.5D, p=0.10), but the amplitude of the locomotor activity rhythm was increased slightly in
the time-restricted feeding females (Fig. S12).
To determine whether time-restricted feeding improved glycemic control in females
lacking circulating estrogens, we performed oral glucose tolerance tests after 7 weeks of highfat diet feeding. The ad libitum-fed females had a greater glucose peak (Fig. 2.5E: at time 15
min; p=0.01) and greater glucose levels overall (main effect p<0.01) compared to time-restricted
feeding females. The rate at which glucose dropped following the peak did not significantly
differ between groups. In sum, glucose tolerance was significantly improved in ovariectomized
females in the time-restricted feeding condition (Fig. 2.5 E,F; AUC: p=0.01). Fasting blood
glucose (Fig. 2.5G, p=0.99) did not differ, but plasma insulin (Fig. S8C, p<0.01) was lower in timerestricted-fed compared to ad libitum-fed females. Thus, improved glucose tolerance was likely
due to improved insulin sensitivity in the time-restricted feeding group since the Homeostatic
Model Assessment of Insulin Resistance (HOMA-IR) was decreased compared to ad libitum-fed
females (Fig. 2.5H, p<0.05).
Since feeding time has been shown to entrain the phase of the liver circadian clock16, we
next tested whether time-restricted feeding altered the phases of the circadian clocks in tissues
in ovariectomized females (Fig. 2.5I, S13, S14). We found that time-restricted feeding did not
alter the phases of the circadian clocks in SCN, pituitary, liver, kidney, lung, and spleen. Notably,
the phase of the liver clock was advanced in both ad libitum-fed and time-restricted feeding
groups, and the magnitude of the phase advance was similar to that in ovariectomized females
fed high-fat diet for 1 week (Fig. 2.4). There was also no significant effect of time-restricted
feeding on the amplitude of the liver clock (Fig. S14B). The phase of the aorta clock was
significantly advanced by time-restricted feeding (p<0.05) compared to long-term high-fat diet
feeding in the ad libitum-fed group (Fig. S13).
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Figure 2. 5. Time-restricted feeding inhibits diet-induced obesity and glucose intolerance in
ovariectomized mice.
Ovariectomized mice were fed high-fat diet either ad libitum (red) or only during the 12-h dark
phase (time-restricted feeding; black), beginning at 8 weeks old (indicated by arrow in A). Mean
(±S EM) body weights were measured weekly (A) and adiposity was measured at 14 weeks old
(B). Energy intake (C) and activity counts (D) were summated from 8 weeks old through 14
weeks old. A-D: n=16 ad libitum; n=19 time-restricted feeding. Mean blood glucose (E) and area
under the curve (F, arbitrary units) are shown for glucose tolerance tests performed at ZT 6
(mice were fasted ZT0-6) at 15 weeks old (n=11/group). Fasting blood glucose (G) and HOMA-IR
(H) (n=6-7/group) were measured at 16 weeks old. I. The mean phases (±SEM, n=4-6/group) of
the peaks of the bioluminescence rhythms of tissues cultured from ovariectomized females fed
high-fat diet ad-libitum (red) or time-restricted (black) were plotted relative to last lights on.
The phases of tissues explanted from intact females (gray) fed high-fat diet for 1 week are
shown for reference. Light and dark is indicated by the white and black bars, respectively.
*p<0.05
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Together these data demonstrate that the high-fat diet-disrupted eating rhythm in
ovariectomized females is responsible, in part, for diet-induced obesity and impaired glucose
homeostasis in females lacking circulating estrogens. Moreover, the beneficial effects of timerestricted feeding occur without altering the phase of the liver circadian clock in ovariectomized
females.

Discussion
It is becoming apparent that weight gain is not simply due to an imbalance between
energy consumed and energy expended. Recent studies in humans and rodents have revealed
that the timing of behaviors, such as food intake, also affect energy balance and glucose
homeostasis396-406. A drawback of these studies is that most were performed in males. As a
result, we know relatively little about the role of daily rhythms and timing in regulating
metabolic dysfunction in females.
In male mice, high-fat diet feeding causes profound obesity and disrupts daily rhythms.
For example, males typically have a high-amplitude eating rhythm (eating consolidated during
the night) when fed low-fat diet388,389. In contrast, when fed high-fat diet, male mice eat
throughout the day and become obese388,389. Restricting high-fat diet feeding to the active phase
inhibits diet-induced obesity, demonstrating that disruption of the daily eating rhythm is a
mechanism of high-fat diet-induced obesity in males396,400,405.
Female mice, like males, have high-amplitude nocturnal eating rhythms on low-fat
diet230,388,389. But, unlike males, we previously found that females retain high-amplitude
nocturnal eating behavior rhythms even when fed high-fat diet230. In this study, we found that
this high-amplitude eating behavior rhythm is abolished by ovariectomy but reinstated in
ovariectomized females treated with physiological doses of E2 (Fig. 2.6). Importantly, the highamplitude eating behavior rhythm conferred by estrogens in females contributes to their
resistance to diet-induced obesity because we inhibited diet-induced obesity in ovariectomized
females by repairing their eating rhythms with time-restricted feeding (Fig. 2.6C).
The neural substrate where E2 acts to regulate the daily rhythm of eating behavior is
unknown. The SCN is necessary for the daily rhythm of food intake since this rhythm is abolished
in SCN-lesioned rodents407. However, we speculate that E2 acts downstream of the SCN to
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inhibit the effect of high-fat diet on the eating rhythm. This is because we found that the phase
and amplitude of the SCN PER2::LUC rhythm are the same in females with and without
circulating E2 during high-fat diet feeding, even though their eating rhythms are markedly
different. This is similar to our previous studies in male mice because their SCN rhythms are also
not affected, even though their eating rhythms are markedly disrupted, during high-fat diet
feeding. We propose that there is a neural locus or neural circuit that is downstream of the SCN
and it regulates the daily rhythm of eating behavior and responds to E2.
In this study we also found that the locomotor activity rhythm is regulated by E2 in
response to high-fat diet feeding. Previous studies have shown that E2 regulates the amplitudes
and phases of daily rhythms of locomotor activity in female mice fed low-fat diets (reviewed
in408). Consistent with previous studies, ovariectomy reduced the overall level of activity in
females in our study409. However, the remarkable difference between ovariectomized females
treated with vehicle and those with E2 replacement was the response of the activity rhythm to
high-fat diet feeding. In females without circulating estrogens, the activity rhythm was identical
during low-fat diet and high-fat diet feeding. In contrast, the amplitude of the activity rhythm
increased 1.5-fold during high-fat diet feeding, compared to low-fat diet feeding, in
ovariectomized females with E2 replacement (Fig. 2.6). Therefore, the function of E2 in females
is to enhance the amplitude of the activity rhythm in the face of a nutritional challenge.
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Figure 2. 6. Proposed model of circadian regulation of diet-induced obesity in female mice.
In females with physiological levels of circulating estradiol (A), daily rhythms are not disrupted
by high-fat diet feeding and the mice are resistant to obesity and metabolic dysfunction.
When circulating estradiol is very low (B), consumption of high-fat diet disrupts daily rhythms
and the mice develop severe obesity and insulin resistance. When the eating rhythm is
restored by time-restricted feeding (food available only during the 12-h active phase) in
females with low circulating estradiol, the mice have improved insulin resistance and only
moderate obesity.
We previously showed that a striking effect of high-fat diet feeding on male mice is that
the phase of the liver circadian clock is advanced by ~5h after only 1 week of high-fat diet
feeding389. The advanced liver phase persists during chronic high-fat diet feeding and coincides
with reorganization of the phases of liver transcriptome rhythms390,410. While it is unknown
whether the effects of high-fat diet feeding on the liver circadian clock directly contribute to
diet-induced obesity, it is clear that high-fat diet has large-scale effects on liver rhythms410. In
contrast to males, in this study we found that the phase of the liver circadian clock is not
affected by high-fat diet feeding in females with physiological levels of circulating estrogens (in
intact females and ovariectomized females with E2 replacement)230. But when females are
ovariectomized and circulating estrogens are undetectable, the phase of the liver advances ~4
hours. Therefore, E2 inhibits the effects of high-fat diet feeding on the phase of the liver in
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female mice (Fig. 2.6). Future studies are necessary to determine whether this occurs via the
direct action of E2 on hepatocytes or indirectly via E2 regulation of behavior.
Estrogens have been shown to have numerous anti-diabetic actions in females411. This
study shows that an additional anti-diabetic function of E2 is to regulate an array of behavioral
and tissue circadian rhythms during high-fat diet feeding. The molecular mechanisms of E2
regulation of the circadian system are unknown and will likely be complex. Estrogens signal via
the classical estrogen receptors, estrogen receptor α and estrogen receptor β, using genomic or
non-genomic modes of action (reviewed in412). More recently, G-protein coupled receptor 30
was identified as an estrogen-binding receptor (and thus called GPER)413. Each estrogen signaling
mechanism controls metabolism in rodents and is a candidate for regulating daily metabolic
rhythms in females240,379,414-416.
Previous studies have shown that ovariectomy impairs glucose tolerance in female
mice232,378,409. This impaired glucose tolerance is due, in part, to reduced secretion of the
glucose-regulating hormone insulin in ovariectomized mice compared to intact females378. In
this study, time-restricted feeding improved glucose tolerance in ovariectomized females by
decreasing insulin resistance. Thus, our behavioral intervention overrides glucose dysregulation
caused by ovariectomy. Our data are consistent with a previous study that showed that 8-h
nighttime-restricted feeding caused weight loss and improved glucose tolerance in obese
ovariectomized female mice397. It is important to note that time-restricted feeding in our study
and in the study by Chung et al. did not restore body weight and fasting glucose in
ovariectomized mice to the level of intact females with circulating estrogens (Fig. 2.6C) 397. In
this study we found that the phase of the liver circadian clock was not rescued by timerestricted feeding. Therefore, it is possible that the misalignment of the liver circadian clock
caused by high-fat diet feeding contributes to metabolic dysfunction in ovariectomized females
that cannot be treated with time-restricted feeding. In sum, time-restricted feeding is an
effective method of improving, but not eliminating, diet-induced obesity and glycemic control in
female mice lacking circulating estrogens.
Removal of ovarian hormones by surgical ovariectomy in mice mimics metabolic
dysfunction in postmenopausal women231,232,377,378,409,417. Ovariectomized female mice fed highfat diet develop diet-induced obesity and become insulin resistant. Likewise, compared to
premenopausal women, postmenopausal women have impaired glucose homeostasis and
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increased risk of type 2 diabetes411. In mice, we find there are sex differences in diet-induced
obesity that are regulated by the circadian system. A function of E2 in female mice is to inhibit
the disruption of behavioral and molecular rhythms by high-fat diet feeding (Fig. 2.6). Together,
this study suggests that the circadian system can be a target for treating obesity and its
comorbidities in women after menopause, when circulating levels of estrogens are too low to
protect their circadian rhythms.
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Supplemental Material
Estradiol regulates daily rhythms underlying diet-induced obesity in female mice

Supplemental Figures

Figure S2. 1. Silastic tubing implants containing 17β-estradiol (E2) delivered physiological
doses of E2 to female mice.
At 6 weeks old, female C57BL6J mice were ovariectomized and treated with Silastic tubing
containing either vehicle (sesame oil; OVX + vehicle: red) or 17β-estradiol (25µg dissolved in
sesame oil, OVX + E2: blue). One, 2, or 3 weeks after surgery, OVX + E2 mice were killed and the
uteri were weighed. OVX + vehicle and intact (not ovariectomized; gray) females were killed at 9
weeks old, which is equivalent to the 3-week timepoint of the OVX + E2 mice. Data are mean ±
SEM of 4-9 mice/group. One-way ANOVA p<0.001. *p<0.05 vs. Intact (post-hoc Bonferroni Test).
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Figure S2. 2. Diagrams of Experimental Protocols.
In Experiment I (A), female C57BL/6J mice, that were either wild-types (n=31) or heterozygous
PER2::LUC (n=22), were ovariectomized at 6 weeks old. At the time of the ovariectomy surgery,
mice were implanted with Silastic tubing containing vehicle (sesame oil, OVX + veh, n=26) or
17β-estradiol (OVX + E2; n=27). At 7 weeks old, all mice were single-housed in light-tight boxes
(12L:12D) and fed low-fat diet (LFD) for 1 weeks and then 45% kcal fat high-fat diet (HFD) for 1
week. At 9 weeks old, bioluminescence rhythms were measured from tissues explanted from
the PER2::LUC mice (n=11/group). In the wild-types (n=15-17/group), mice were fasted from
ZT3-10. Then they were killed at ZT10 and blood glucose and body composition were measured.
Locomotor activity was measured in all mice and eating behavior was measured in n=17/group.
In Experiment II (B), female C57BL/6J mice, that were either wild-types (n=23) or heterozygous
PER2::LUC (n=12), were ovariectomized at 6 weeks old. At 7 weeks old, all mice were singlehoused in light-tight boxes (12L:12D) and fed LFD for 1 week. At 8 weeks old, all mice were fed
HFD for 8 weeks either ad libitum (n=16) or only during the 12h dark phase (n=19). Locomotor
activity and food weight at ZT0 and ZT12 were measured in all mice. Body composition was
measured at 14 weeks old and oral glucose tolerance tests were performed at 15 weeks old.
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Figure S2. 3. Eating behavior rhythms in individual ovariectomized mice.
Females were ovariectomized and implanted with silastic tubing containing vehicle. Circular
histograms of eating behavior rhythms during low-fat diet feeding (left panels) and high-fat diet
feeding (right panels) for all individual mice are shown. The mouse in A is also shown in Fig. 2.2
C,D. White shading indicates lights on (ZT0-12) and gray shading shows lights off (ZT12-0). The
arrows are the vectors determined by the Rayleigh Uniformity test.
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Figure S2. 4. Eating behavior rhythms in individual ovariectomized mice treated with estradiol.
Females were ovariectomized and implanted with Silastic tubing containing 17β-estradiol.
Circular histograms of eating behavior rhythms during low-fat diet feeding (left panels) and highfat diet feeding (right panels) for all individual mice are shown. The mouse in A is also shown in
Fig. 2.2 E,F. White shading indicates lights on (ZT0-12) and gray shading shows lights off (ZT120). The arrows are the vectors determined by the Rayleigh Uniformity test.

58

Figure S2. 5. High-fat diet feeding reduced the number of eating events in ovariectomized
mice treated with vehicle or estradiol.
Females were ovariectomized (OVX) and implanted with Silastic tubing containing either vehicle
(A) or 17β-estradiol (E2; B). The mean numbers (± SEM) of eating events during one day of lowfat diet (LFD) and one day of high-fat diet (HFD) feeding are shown. The number of eating events
was similarly reduced during HFD feeding in both groups. These data show that the homeostatic
response to HFD, which is to reduce intake because HFD has more calories per gram than LFD, is
not affected by circulating estradiol. In addition, these data show that the reduction in vector
length (which we define as the amplitude of the eating behavior rhythm; Fig. 2.2G) is not due to
a reduction in the number of eating events in the vehicle-treated group, because the number of
eating events are reduced in both groups, but the vector length is reduced in only the vehicletreated group. *p<0.001 (Mann-Whitney).
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Figure S2. 6. Locomotor activity rhythms in individual ovariectomized mice.
Females were ovariectomized and implanted with silastic tubing containing vehicle (sesame oil).
Actograms (scaled: max 7 counts/6-min bin) of locomotor activity measured by passive infrared
sensors during low-fat diet feeding (LFD) and high-fat diet feeding (HFD) for all individual mice
are shown. Red asterisk shows when LFD was changed to HFD. The mouse in A is also shown in
Fig. 2.3A. Lights were on from 0-12 and off from 12-24 (indicated by white and black bar,
respectively). x-axis: days; y-axis: time (hours).
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Figure S2. 7. Locomotor activity rhythms in individual ovariectomized mice treated with
estradiol.
Females were ovariectomized and implanted with silastic tubing containing 17β-estradiol.
Actograms (scaled: max 7 counts/6-min bin) of locomotor activity measured by passive infrared
sensors during low-fat diet feeding (LFD) and high-fat diet feeding (HFD) for all individual mice
are shown. Red asterisk shows when LFD was changed to HFD. The mouse in A is also shown in
Fig. 2.3B. Lights were on from 0-12 and off from 12-24 (indicated by white and black bar,
respectively). x-axis: days; y-axis: time (hours).
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Figure S2. 8. Phases of locomotor activity rhythms are not altered by high-fat diet feeding in
ovariectomized females.
Mean phases (±SEM) of locomotor activity rhythms, measured by passive infrared sensors, of
ovariectomized females treated with vehicle (A) or 17β-estradiol (E2, B). Mice were fed LFD for 1
week and HFD for 1 week. n=17 mice/group.
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Figure S2. 9. The amplitudes of the SCN and liver circadian clocks are not affected by
circulating estradiol in females fed high-fat diet.
Mean amplitudes (±SEM) of PER2::LUC rhythms in SCN (A, n=5-7/group) and livers (B, n=510/group) explanted from intact females (gray), or from ovariectomized females treated with
vehicle (red) or 17β-estradiol (E2, blue) were determined as previously described418. Mice were
fed LFD for 1 week and HFD for 1 week. There were no significant differences between the groups
(one-way ANOVA) in the amplitude of the SCN (p=0.45) or liver (p=0.69) circadian clock.
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Figure S2. 10. Effects of time-restricted feeding on metabolic parameters in ovariectomized
females.
At 16 weeks old, ovariectomized females fed ad libitum (red) or time-restricted (black) were
fasted from ZT0-8. Total plasma cholesterol (A), triglycerides (B), and insulin (C) were analyzed
from blood collected at ZT8. n=6-7/group. Data are mean ± SEM. *p<0.01.
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Figure S2. 11. Energy intake during time-restricted feeding.
Cumulative energy intake (A) was greater in ad libitum-fed (red) compared to time-restricted-fed
(black) ovariectomized female mice (mixed measures ANOVA time x group p<0.01). Mean food
intake (B) during the light (white) and dark (gray) phases in ad libitum-fed mice (time-restricted
feeding mice ate all food during the dark phase). Data are mean ± SEM. *p<0.05.
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Figure S2. 12. Locomotor activity rhythms in ad libitum- and time-restricted fed
ovariectomized mice.
Mean activity profiles (A) of ovariectomized mice fed high-fat diet ad libitum (red) or only during
the 12-h dark phase (black: time-restricted feeding). Activity counts were measured passive
infrared sensors and average from 8 weeks old until 14 weeks old (in 6-min bins). The sharp
peaks at light on (time 0) and lights out (time 12) were caused by weighing the food. Cosinor
analysis was used to determine the mean (±SEM) mesor (B), amplitude (C), and phase (D) of the
activity rhythms. *p<0.01.
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Figure S2. 13. Phases of central and peripheral circadian clocks during ad libitum- and timerestricted feeding of females without circulating estrogen.
Ovariectomized mice were fed HFD either ad libitum (red) or only during the 12-h dark phase
(time-restricted feeding; black) for 8 weeks. The mean phases (±SEM; n=4-6/group) of the peaks
of the PER2::LUC bioluminescence rhythms were plotted relative to last lights on. Light and dark
is indicated by the white and black bars, respectively. *p<0.05
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Figure S2. 14. The amplitudes of the SCN and liver circadian clocks are not affected by timerestricted feeding in ovariectomized females fed high-fat diet.
Ovariectomized PER2::LUC female mice were fed high-fat diet either ad libitum (red) or only
during the 12-h dark phase (black) for 8 weeks. SCN (A, n=4-5/group) and livers (B, n=4/group)
were cultured and bioluminescence was measured. The mean amplitudes (±SEM) were
determined using LumiCycle software as previously described418. Samples with a goodness-of-fit
less than 90% were excluded. There were no significant differences between the groups in the
amplitude of the SCN (p=0.61) or liver (p=0.21) circadian clock.
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Table S2.1 1. Composition of diets purchased from Research Diets, Inc.
Product #

D12450K (LFD)
gm
%kcal
19.2
20
67.3
70
4.3
10
90.8
100
3.85

D01060502 (HFD)
gm
%kcal
23.7
20
41.4
35
23.6
45
88.7
100
4.73

Casein, lactic
Cysteine, L

200
3

800
12

200
3

800
12

Corn starch
Maltodextrin 10
Dextrose
Sucrose

550
150
0
0

2200
600
0
0

221
125
0
0

882
500
0
0

Cellulose BW500

50

0

50

0

Soybean oil, USP
Lard

25
20

225
180

25
177.5

225
1598

10
13
5.5
16.5

0
0
0
0

10
13
5.5
16.5

0
0
0
0

10
2

40
0

10
2

40
0

0.025
0.025

0
0

0
0.05

0
0

Protein
Carbohydrate
Fat
Total
Kcal/gm
Ingredients

Mineral Mix S10026
DiCalcium phosphate
Calcium carbonate
Potassium citrate, 1 H20
Vitamin mix V10001
Choline bitartrate
FD&C red dye #40
FD&C blue dye #1
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CHAPTER 3: CIRCADIAN ORGANIZATION IN MAE AND FEMALE ESTROGEN RECEPTOR
KNOCKOUT MICE

Introduction
Circadian rhythms are physical, physiological, and behavioral changes that fluctuate
every 24 hours419. There are molecular circadian clocks in nearly every tissue in the body that
intrinsically generate rhythms that have periods of approximately 24 hours16,59,62. These internal
clocks are entrained by exogenous cues such as the light-dark cycle so that circadian rhythms
are coordinated with the environment420. The suprachiasmatic nucleus (SCN), located in the
hypothalamus, is the main circadian clock in the body17,18. The SCN is at the top of hierarchical
organization of circadian clocks in mammals. Information about the level of light in the
environment is detected primarily by the intrinsically photosensitive retinal ganglion cells
(ipRGCs)63. The SCN then receives input about the light/dark cycle directly from the ipRGCs via
the retino-hypothalamic tract (RHT)19. The SCN thus entrains to the light-dark cycle and then
functions to synchronize the timing, or phases, of the circadian clocks in nearly every tissue in
the body to that of the external environment20,21. The coordination of the phases of circadian
tissue clocks with each other and with the environment is known as circadian organization.
Disruption of circadian organization has been linked to adverse health outcomes such as cancer
and metabolic disorderrs22-26.
Estrogens are reproductive hormones mainly produced in the gonads but also in the
brain, bone, and adipose tissues76,79. Estrogens exert their effects via 3 major estrogen receptors
(ERs): ERα, ERβ, and G protein-coupled estrogen receptor 1 (GPER1)80. ERα and ERβ can signal
via genomic mechanisms by acting as transcription factors that bind to estrogen response
elements (EREs) in target genes or rapid non-genomic mechanisms via membrane-bound ERα,
ERβ, and GPER1. ERs are expressed throughout the body75,89,114.
Previous studies have shown that there is interplay between estrogens and the circadian
system123,421,422. The locomotor activity rhythm in female rodents is affected by fluctuating
estrogen levels across the estrous cycle, this is called scalloping activity. The scalloping activity
pattern is lost after removal of circulating estrogens by ovariectomy (OVX)360,361. OVX also
lengthens the free-running period of activity and reduces the magnitude of phase delays of
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activity to light pulses, while estradiol treatment shortens the free-running period of
activity185,248,360,361.
Estrogens can also regulate the molecular circadian timekeeping mechanism in tissues.
The mechanisms by which estrogens alter circadian rhythms are unknown. However, several
circadian genes, including Per1, Per2, and Clock have EREs in their regulatory regions and thus
could be under estrogenic control368,373,423. Estradiol treatment also altered expression of the
circadian gene, Per2, in explanted peripheral tissues such as liver and uterus367,423.These studies
have generally found that effect of estrogen control on circadian gene expression differs
between tissues.
While it is known that estrogens regulate tissue circadian clocks, the effects of disabling
estrogen receptor signaling on circadian organization have not been well-studied. Thus, our goal
was to study circadian organization and molecular timekeeping rhythms in central and
peripheral tissues in male and female mice lacking functional ERα, ERβ and GPER1.

Methods and materials
Animals
ERα KO (strain #026176), ERβ KO (strain #004745), and GPER1 KO (strain #030841) mice
were purchased from The Jackson Laboratory. ERα KO mice were generated by deletion of exon
3 of chromosome 10 and were acquired on a mixed C57BL/6NJ and C57BL/6NCrl background176.
We backcrossed ERα heterozygous mice to heterozygous PERIOD2::LUCIFERASE C57BL/6J60
(N32-N33) mice in our colony for 4 to 5 generations. ERβ KO mice were generated by insertion
of a stop codon in exon 3 of chromosome 12 and were on a mixed C57BL/6J and C57BL/6NTac
backgound180. We backcrossed ERβ heterozygous mice to heterozygous PERIOD2::LUCIFERASE
C57BL/6J60 (N32-N33) mice in our colony for 2 to 5 generations. GPER1 KO mice were generated
by replacement of exon 3 on chromosome 5 with a neo cassette and were on an C57BL/6J
background260. We backcrossed GPER1 heterozygous mice to heterozygous
PERIOD2::LUCIFERASE C57BL/6J60 (N32-N33) mice in our colony for 2 to 4 generations. To
generate littermates that were WT and KO for the receptor gene for experiments, breeders that
were heterozygous for the receptor genes were intercrossed. One parent was also heterozygous
PERIOD2::LUCIFERASE. All mice used for experiments were heterozygous PER2::LUC.
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Breeders and offspring were housed in 12L:12D and fed standard rodent diet (Teklad 2918, 18%
kcal fat, 3.1 kcal/g metabolizable energy) and water ad libitum. Pups were weaned at 21 days of
age and group-housed (2–5 same-sex mice/cage). Tail snips were collected at weaning and
genotyped by measuring luminescence with a luminometer and performing PCR for each ER
genotype. PCR protocols for ERα KO, ERβ KO, and GPER1 KO mice were from The Jackson
Laboratory website. All procedures were approved by the Institutional Animal Care and Use
Committee at the University of Kentucky (protocols 2015-2211 and 2021-3842).
Bioluminescence Recording and Analysis
Mice used for experiments were group housed in 12L:12D and fed standard rodentdiet
(Teklad 2918) and water ad libitum. At age 6-20wks old, heterozygous PER2::LUC male and
female ERα WT and KO mice, ERβ WT and KO mice, and GPR30 WT and KO mice were
euthanized by cervical dislocation and decapitated within 1.5 h before lights out (ZT10.5–12).
Coronal slices of the suprachiasmatic nucleus (SCN) (250 µm) and explants of aorta, liver, lung,
soleus muscle, and white adipose tissue (WAT) were dissected and cultured to measure
bioluminescence as previously described66,394. Tissue bioluminescence was measured in 10-min
bins with the LumiCycle apparatus (Actimetrics). Data were smoothed and detrended using
LumiCycle Analysis software (Actimetrics). The acrophases of bioluminescence expression in
each tissue were determined between 12 and 36 h in culture using ClockLab Analysis software
(Actimetrics). The amplitudes of bioluminescence expression in each tissue were determined
between 12 and 36h in culture using a sine fit curve in LumiCycle Analysis software
(Actimetrics). Tissues with a goodness of fit less than 90% were excluded from the amplitude
analyss. The periods of bioluminescence expression in each tissue were determined with a
regression line fitted to 3 or more days of acrophase using ClockLab Analysis software
(Actimetrics). The period of PER2::LUC rhythm in liver cultures changes after about three
cycles389. The periods reported for liver explants are the first periods measured from the first 3
cycles in culture.
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Statistical Analysis
The phases, amplitudes, and periods of tissue PER2:LUC rhythms were analyzed
separately for each tissue and each estrogen receptor by two-way ANOVA with sex and
genotype as factors, followed by Fisher LSD post hoc tests. Significance was ascribed at p<0.05.
Results
Circadian organization in ERα KO mice
We first measured PER2::LUC rhythms in central and peripheral tissues explanted from
global ERα WT and ERαKO male and female mice. We found that circadian organization was
altered by global deletion of ERα (Fig. 3.1). The phases of PER2::LUC rhythms in the SCN and
liver were advanced in both male and female ERαKO mice compared to ERα WT mice (Fig. 3.1).
The phases of PER2::LUC expression in the aorta, lung, muscle, and WAT were not altered by sex
or ERα deletion. The periods and amplitudes of PER2::LUC expression rhythms did not differ by
sex or genotype in in the explanted aorta, liver, lung, muscle, SCN, and WAT (Table 3.1).
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Figure 3. 1. Circadian organization of global ERα WT and ERα KO mice.
Mean phases (± SEM) of bioluminescence rhythms recorded from tissues explanted from
female ERαWT (pink circle), female ERαKO (red circle), male ERαWT (pink triangle), and male
ERαKO (red triangle) mice fed standard rodent diet and maintained in 12L∶12D. Phases are
plotted relative to last time of lights on. Light and dark are indicated by the open and black
bars, respectively. Number of rhythmic samples/number of samples cultured is shown for each
tissue.
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Tissues

Period

Amplitude

Females
ERα WT

ERα KO

Males
ERα WT

ERα KO

Aorta

22.98±0.49
(11)

23.20±0.23
(7)

22.88±0.38
(9)

22.83±0.62
(7)

Liver

19.78±1.26
(9)

20.00±0.41
(6)

20.42±0.20
(10)

20.29±0.20
(7)

Lung

23.33±0.10
(11)

23.23±0.15
(6)

23.13±0.19
(11)

21.96±1.38
(7)

Muscle

22.84±0.14
(9)

22.32±0.15
(7)

22.27±0.17
(10)

22.86±0.19
(7)

SCN

24.36±0.07
(9)

24.24±0.18
(7)

24.49±0.11
(9)

24.35±0.12
(7)

WAT

26.30±0.17
(11)

23.43±1.35
(6)

25.35±1.28
(11)

25.83±1.28
(7)

Aorta

21.92±3.23
(11)

23.46±2.76
(7)

20.98±4.69
(9)

17.80±2.10
(6)

Liver

16.01±3.67
(6)

15.83±1.46
(5)

16.21±2.48
(8)

15.13±1.67
(7)

Lung

26.15±4.27
(11)

24.65±3.10
(6)

24.30±4.54
(10)

26.33±2.52
(7)

Muscle

38.20±5.67
(11)

40.40±6.68
(7)

41.24±7.15
(10)

38.54±4.91
(7)

SCN

40.46±6.38
(8)

42.07±7.18
(7)

45.99±8.91
(8)

44.57±5.99
(7)

WAT

22.59±3.10
(9)

23.22±5.00
(5)

29.02±4.54
(6)

26.79±4.98
(4)

2 Way ANOVA

S: F=0.25, p=0.62
G: F=0.04, p=0.85
S*G: F=0.08, p=0.78
S: F=0.37, p=0.55
G: F<0.05, p=0.95
S*G: F=0.05, p=0.82
S: F=1.60, p=0.22
G: F=1.21, p=0.28
S*G: F=0.85, p=0.36
S: F=0.01, p=0.93
G: F=0.05, p=0.83
S*G: F=10.73, p<0.01*
S: F=0.94, p=0.34
G: F=1.24, p=0.27
S*G: F<0.05, p=0.95
S: F=0.43, p=0.52
G: F=1.17, p=0.29
S*G: F=2.31, p=0.14
S: F=0.78, p=0.39
G: F=0.05, p=0.83
S*G: F=0.40, p=0.53
S: F=0.01, p=0.93
G: F=0.06, p=0.82
S*G: F=0.03, p=0.87
S: F<0.05, p=0.98
G: F<0.05, p=0.95
S*G: F=0.17, p=0.68
S: F=0.01, p=0.93
G: F<0.05, p=0.97
S*G: F=0.14, p=0.71
S: F=0.30, p=0.59
G: F<0.05, p=0.99
S*G: F=0.04, p=0.84
S: F=1.31, p=0.27
G: F=0.03, p=0.86
S*G: F=0.11, p=0.75

Table 3. 1. Periods and Amplitudes of the molecular circadian rhythm measured from
tissues explanted from WT mice or whole-body ERα KO mice.
Number of rhythmic samples cultured is shown for each tissue. Number of samples with
goodness of fit of more than 90% is shown for each tissue.
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Circadian organization in ERβ KO mice
We next studied tissue PER2::LUC rhythms in explanted central and peripheral tissues of
global ERβ WT and ERβ KO male and female mice. Circadian organization was altered by global
deletion of ERβ (Fig. 3.2). The phases of SCN PER2::LUC rhythms were delayed in ERβ KO mice
compared to ERβ WTs (Fig. 3.2; main effect of genotype in SCN, Table 3.2). There was also a
main effect of sex on the phases of SCN rhythms such that females had more delayed phases
compared to males (Fig. 3.2; main effect of sex in SCN, Table 3.2). The phases of PER2::LUC
rhythms in the aorta, liver, lung, muscle, and WAT were not affected by sex or by ERβ deletion.
The periods of SCN rhythms of female ERβ WT and ERβ KO mice were longer than males (Table
3.2). There was no effect of genotype or sex on the periods of the aorta, liver, lung, muscle, and
WAT rhythms. The amplitudes of PER2::LUC expression rhythms did not differ by sex or
genotype in in the explanted aorta, liver, lung, muscle, SCN, and WAT (Table 3.2).
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Figure 3. 2. Circadian phases measured from PER2::LUC rhythms of tissues explanted from
global ERβ WT or KO mice.
Mean phases (± SEM) of bioluminescence rhythms recorded from tissues explanted from
female ERαWT (pink circle), female ERαKO (red circle), male ERαWT (pink triangle), and male
ERαKO (red triangle) mice fed standard rodent diet and maintained in 12L∶12D. Phases are
plotted relative to last time of lights on. Light and dark are indicated by the open and black
bars, respectively. Number of rhythmic samples/number of samples cultured is shown for
each tissue.
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Period

Tissues

Females
ERβ WT

ERβ KO

Males
ERβ WT

ERβ KO

Aorta

23.59±0.14
(6)

23.33±0.28
(7)

23.37±0.09
(9)

23.51±0.25
(5)

19.47±0.34
(6)

19.97±1.27
(6)

20.41±0.33
(10)

20.43±0.24
(5)

23.38±0.08
(6)

23.27±0.18
(7)

23.32±0.11
(11)

23.29±0.39
(5)

22.67±0.21
(6)

22.53±0.10
(7)

22.53±0.07
(10)

22.63±0.11
(5)

24.48±0.08
(6)

24.51±0.13
(7)

24.20±0.11
(9)

24.03±0.39
(5)

26.35±0.17
(6)

26.76±0.33
(7)

26.90±0.35
(11)

26.74±0.30
(5)

24.90±4.28
(6)

21.02±3.35
(7)

25.76±3.61
(9)

22.98±3.41
(5)

15.45±4.51
(4)

15.59±2.45
(4)

23.83±5.90
(8)

15.58±1.08
(4)

29.85±6.03
(6)

20.66±1.56
(7)

26.71±5.33
(10)

24.11±3.42
(5)

44.71±7.11
(6)

41.62±6.65
(7)

45.99±5.22
(10)

38.66±11.31
(5)

39.70±4.08
(6)

35.85±8.94
(6)

37.88±7.04
(8)

47.47±7.73
(4)

25.73±6.00
(5)

24.34±8.25
(7)

24.47±2.09
(6)

23.20±6.03
(4)

Liver

Lung

Muscle

SCN

WAT

Amplitude

Aorta

Liver

Lung

Muscle

SCN

WAT

2 Way ANOVA
S: F=0.01, p=0.93
G: F=0.08, p=0.78
S*G: F=0.25, p=0.32
S: F=1.13, p=0.30
G: F=0.15, p=0.70
S*G: F=0.13, p=0.71
S: F=0.01, p=0.93
G: F=0.11, p=0.74
S*G: F=0.04, p=0.85
S: F=0.03, p=0.86
G: F=0.03, p=0.86
S*G: F=0.95, p=0.34
S: F=4.61, p=0.04*
G: F=0.15, p=0.70
S*G: F=0.31, p=0.57
S: F=0.60, p=0.45
G: F=0.15, p=0.70
S*G: F=0.71, p=0.41
S: F=0.14, p=0.71
G: F=0.79, p=0.38
S*G: F=0.02, p=0.89
S: F=0.43, p=0.52
G: F=0.40, p=0.53
S*G: F=0.43, p=0.52
S: F<0.05, p=0.98
G: F=1.38, p=0.25
S*G: F=0.43, p=0.52
S: F=0.01, p=0.91
G: F=0.51, p=0.48
S*G: F=0.08, p=0.77
S: F=0.41, p=0.53
G: F=0.14, p=0.71
S*G: F=0.76, p=0.39
S: F=0.03, p=0.86
G: F=0.04, p=0.84
S*G: F<0.05, p=0.99

Table 3. 2. Periods and Amplitudes of the molecular circadian rhythm measured from tissues
explanted from WT mice or whole-body ERβ KO mice.
Number of rhythmic samples cultured is shown for each tissue. Number of samples with
goodness of fit of more than 90% is shown for each tissue.
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Circadian organization in GPER1 KO mice
We next studied PER2::LUC rhythms in tissues explanted from GPER1 WT and GPER1 KO
mice. The phases of PER2::LUC expression in the aorta, liver, lung, muscle, SCN, WAT were not
affected by sex or by global GPER1 deletion (Fig. 3.3). The periods of liver PER2::LUC rhythms
were lengthened in GPER1 KO mice of both sexes, but not in any other tissues (Table 3.3). There
was also a main effect of sex and female mice had shorter liver periods than male mice (Table
3.3). There was no effect of sex or GPER1 KO on the amplitudes of PER2::LUC rhythms in aorta,
liver, lung, muscle, SCN, and WAT (Table 3.3).

Figure 3. 3. Circadian organization in GPER1 KO mice.
Mean phases (± SEM) of bioluminescence rhythms recorded from tissues explanted from
female ERαWT (pink circle), female ERαKO (red circle), male ERαWT (pink triangle), and male
ERαKO (red triangle) mice fed standard rodent diet and maintained in 12L∶12D. Phases are
plotted relative to last time of lights on. Light and dark are indicated by the open and black
bars, respectively. Number of rhythmic samples/number of samples cultured is shown for
each tissue.
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Period

Tissues

Females
GPER1 WT

GPER1 KO

Males
GPER1 WT

GPER1 KO

Aorta

23.74±0.33
(6)

23.61±0.19
(9)

23.62±0.28
(6)

23.28±0.19
(8)

19.45±0.28
(6)

20.60±0.37
(8)

20.53±0.20
(7)

20.91±0.27
(8)

23.40±0.09
(7)

23.27±0.09
(9)

23.33±0.08
(7)

23.59±0.16
(8)

22.70±0.24
(6)

22.63±0.09
(10)

22.75±0.15
(7)

22.66±0.12
(8)

24.37±0.07
(7)

24.35±0.08
(10)

24.38±0.24
(7)

24.50±0.21
(7)

26.30±0.30
(7)

26.28±0.25
(10)

26.15±0.70
(6)

27.20±0.36
(8)

24.85±5.72
(4)

23.27±6.00
(8)

25.36±5.78
(6)

25.69±5.44
(6)

15.01±1.77
(6)

16.01±2.00
(7)

15.40±0.62
(5)

15.75±1.68
(8)

23.11±2.78
(6)

27.18±6.48
(9)

26.35±3.13
(7)

29.47±4.58
(8)

43.75±13.55
(6)

40.32±5.39
(10)

46.24±4.58
(7)

42.40±3.96
(8)

44.95±9.36
(7)

41.52±8.99
(9)

37.31±8.65
(6)

48.62±13.47
(7)

43.75±13.55
(6)

40.32±5.39
(9)

46.24±4.58
(5)

42.40±3.96
(4)

Liver

Lung

Muscle

SCN

WAT
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2 Way ANOVA
S: F=0.85, p=0.36
G: F=0.96, p=0.33
S*G: F=0.20, p=0.66
S: F=5.46, p=0.03*
G: F=6.63, p=0.02*
S*G: F=1.69, p=0.21
S: F=1.32, p=0.26
G: F=0.36, p=0.55
S*G: F=2.99, p=0.10
S: F=0.08, p=0.78
G: F=0.31, p=0.58
S*G: F=0.01, p=0.93
S: F=0.26, p=0.61
G: F=0.12, p=0.73
S*G: F=0.21, p=0.65
S: F=0.95, p=0.34
G: F=1.72, p=0.20
S*G: F=1.84, p=0.19
S: F=0.05, p=0.82
G: F=0.01, p=0.92
S*G: F=0.02, p=0.88
S: F=0.00, p=0.97
G: F=0.15, p=0.70
S*G: F=0.03, p=0.85
S: F=0.30, p=0.59
G: F=0.51, p=0.48
S*G: F=0.01, p=0.93
S: F=0.11, p=0.75
G: F=0.27, p=0.61
S*G: F<0.05, p=0.98
S: F<0.05, p=0.98
G: F=0.15, p=0.70
S*G: F=0.52, p=0.48
S: F=0.11, p=0.75
G: F=0.27, p=0.61
S*G: F<0.05, p=0.98

Table 3. 3. Periods and Amplitudes of the molecular circadian rhythm measured from tissues
explanted from WT mice or whole-body GPER1 KO mice.
Number of rhythmic samples cultured is shown for each tissue. Number of samples with
goodness of fit of more than 90% is shown for each tissue.
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Discussion
In this study we investigated whether disabling the functions of ERα, ERβ and GPER1 in
male and female mice affected the molecular circadian timekeeping mechanism in central and
peripheral clocks. Previous studies showed that estrogens regulate the expression of the
circadian genes, Per1, Per2, and Clock, by binding to EREs that are present in the regulatory
regions of these genes368,373,423. We used the PERIOD2::LUCIFERASE reporter in our experiments.
Period2 has an ERE and prior studies have shown that its expression is regulated by estradiol in
ERα positive breast (MCF-7, T47D) and endometrial (Ishikawa) cancer cell lines and also in
central (SCN and cerebral cortex) and periphery (liver, kidney, and uterus) tissues 368. 423,367.
Thus, we hypothesized that ERα KO and ERβ KO mice would have altered PER2::LUC expression
in tissues since these are the estrogen receptor types that signal by binding to EREs.
We found that circadian organization was disrupted in ERα KO and ERβ KO mice, but not
in GPER1 KO mice. The phase of the SCN rhythm was altered in both ERα KO and ERβKO mice.
However, the phase the SCN was advanced ~0.6h in ERα KO mice but delayed ~0.7h in ERβ KO
mice. An advanced phase could be caused by period shortening and a delayed phase by period
lengthening, thus we analyzed the periods of the SCN rhythms. We found there were no effects
of ERα KO or ERβ KO on the periods of the SCN rhythms to account for the phase changes.
The three ER types are expressed in the SCN. ERβ and ERα receptors are localized in the
mouse SCN shell but with many more ERβ expressing cells and sparse ERα expression424-427. SCN
rhythms could also be indirectly affected by estrogen signaling in nuclei that project to the SCN.
For example, ERα-expressing cells in the arcuate and preoptic area project to the SCN428.
Therefore, the alterations in the phases of the SCN GPER1 is highly expressed in the SCN, but
there was no effect of GPER1 KO on the phase, period, or amplitude of the SCN rhythm429. It is
possible that other rhythms in the SCN, such as the neuronal firing rate, could be affected in
GPER1 KO mice. A previous study showed that estradiol treatment increased SCN firing
activity430,431. This effect might be due to signaling via membrane bound ERs, like GPER, that are
localized in the SCN429.
Prior studies have reported conflicting findings about the ability of estrogens to regulate
circadian gene expression in the SCN. In one study, the SCN PER2::LUC rhythm did not differ in
high vs. low estrogen stages of the estrous cycle372. Another study also showed that estradiol
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treatment did not affect Per2 expression in the SCN. In contrast, one study showed that
estradiol treatment altered the phase of Per2 mRNA expression in the SCN. Our study further
shows that estrogen signaling, specifically ERα and ERβ signaling, regulates the phase of SCN
PER2 expression.
The phase of the liver molecular clock was also advanced by 0.8h in ERα KO mice. The
liver highly expresses ERα84,240,432,433. Our results are consistent with several previous studies
that also showed that estrogen signaling affects the liver circadian clock355(also see Ch. 2). When
the liver was treated with estradiol, the phase of liver PER2::LUC was delayed372. Per2
expression in the liver also varies across the estrous cycle372. Thus, stimulating estrogen signaling
delays the liver phase and removing ERα signaling in our experiment advanced the liver phase.
The liver clock was the only tissue that was affected by GPER1 KO. We found that the
period of the liver PER2::LUC rhythm was lengthened ~0.7h in GPER1 KO mice. This period
lengthening had no effect on the phase of the liver clock in GPER1 KO mice.
Taken together, our results suggest that the global loss of ERα, ERβ, or GPER1 estrogen
signaling leads to mild disruption of the molecular circadian timekeeping mechanisms in certain
tissues. This study shows complex tissue-specific and receptor-specific interactions between
estrogen signaling and the circadian system.
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CHAPTER 4: INVESTIGATING THE ROLE OF ESTROGEN RECEPTOR α IN PROTECTING DAILY
RHYTHMS FROM DISRUPTION BY HIGH-FAT FEEDING IN FEMALE MICE

Introduction
Circadian rhythms are ~24-hour cycles of physiological and behavioral processes, such as
eating rhythms and the sleep-wake cycle, that are synchronized to environmental cues such as
light434. In mammals, the suprachiasmatic nucleus (SCN), located in the hypothalamus, acts as
the main circadian pacemaker. It receives environmental cues about the light/dark cycle from
the retino-hypothalamic tract (RHT) and orchestrates the phases of rhythms in various tissues.
Disruption of the circadian system, which can be caused by living out of sync with the
environmental cycle, is associated with obesity and its related comorbidities435-437.
Male mice rapidly gain weight when they are fed a high-fat diet (HFD)389. In contrast to
males, female mice are resistant to diet-induced obesity438. Studies show that circulating
estrogens protect females from obesity-related disorders439,440. Ovariectomy (OVX), which
virtually eliminates circulating estrogens, abolishes this resistance242,355,441. Previous studies have
shown that diet-induced disruption of circadian rhythms causes obesity in male mice389,390,396.
The robust eating rhythm of male mice fed low-fat diet becomes arrhythmic or low-amplitude
when they are fed HFD355,389. In addition, the phase of the liver molecular circadian rhythm is
advanced by ~5h in HFD-fed male mice 355,389. In contrast, female mice have robust eating
rhythms during LFD and HFD feeding, and their liver rhythm is not affected by HFD feeding355.
Consistent with previous studies I found that OVX females fed HFD became obese,
while estradiol (E2) replacement in OVX mice inhibited HFD-induced obesity231,442,. HFD feeding
decreased the amplitude and advanced the phase of the eating behavior rhythm in OVX mice,
but not in E2-treated OVX mice. In addition, the phase of the liver molecular circadian rhythm
was advanced by ~4h in OVX mice, but not in E2-treated OVX mice fed HFD. These data show
that estrogen protects the integrity of daily metabolic rhythms in female mice.
Circulating estrogens signal via various estrogen receptors (ERs). Estrogen signaling via
estrogen receptor α (ERα) has been shown to reduce the development of metabolic syndrome
in rodents443-445. Whole body ERα KO male and female mice have increased adipose tissue that is
mainly visceral fat239. ERα KO mice also have increased body weight and energy intake and
83

reduced energy expenditure and insulin sensitivity239,242. Propyl pyrazole triol (PPT), which is an
ERα agonist, protects female mice from diet-induced obesity245,246,446-448. Together these studies
show that ERα regulates obesity and metabolism90,239-242.
In this study, we sought to determine if estrogen signaling via ERα is necessary and
sufficient to protect daily rhythms in females from HFD-induced disruption.
Methods and Materials
Animals
C57BL/6J female mice were generated for experiments in our animal facility in 12L:12D.
Whole-body ERα WT and KO female mice were used for experiments449,450. To generate mice for
experiments, heterozygous C57BL/6J ERα KO mice (stock #026176) were purchased from The
Jackson Laboratory. ERα KO mice are infertile so we crossed heterozygous males and females to
generate experimental ERα KO and WT mice for experiments90,176. Heterozygous C57BL/6J
PERIOD2::LUCIFERASE (N28 to N32) in our colony were crossed to ERα KO mice to generate
female ERα WT and ERα KO mice that were also heterozygous for PER2::LUC. Genotyping for
mutant ESR1 and ESR2 alleles was determined by PCR as previously described176,180.
For ERα agonist experiments, heterozygous C57BL/6J PERIOD2::LUCIFERASE (N31 to
N34; backcrossed to C57BL/6J mice purchased from The Jackson Laboratory) were crossed with
wild-type C57BL/6J mice (The Jackson Laboratory stock# 000664) to generate female
heterozygous PER2::LUC and wild-type mice that were used
Breeders and offspring were housed in 12L:12D and fed standard rodent diet (Teklad
2918; 18% kcal fat; 3.1 kcal/g metabolizable energy) and water ad libitum. Pups were weaned
and group-housed (2-5 same-sex mice/cage) at 21 days old. Tail snips were collected from pups
at weaning and genotyped by measuring luminescence with a luminometer. All procedures were
submitted to and approved by the Institutional Animal Care and Use Committee at the
University of Kentucky (protocol number 2015-2211 and 2022-3842).
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Experimental Protocols
Experiment 1: ERα KO female mice
At 7 weeks old, ERα WT and KO mice were weighed and individually housed in cages
(33 cm × 17 cm × 14 cm) with locked running wheels in light-tight boxes in 12L:12D (250-350 lux,
white LEDs). Mice were fed low-fat diet (10% kcal fat; 3.85 kcal/g, Research Diets D12450K) for 1
week (7 to 8 weeks old) and then HFD (45% kcal fat; 4.73 kcal/g, Research Diets D01060502) for
6 weeks (8 to 14 weeks old). The 45% kcal HFD is equivalent to the fat percentage of total
dietary energy consumed in the standard American diet391. Body weight and food consumption
were measured weekly within 3h before lights out (~Zeitgeber time (ZT) 9-12, where ZT 0 is
lights on and ZT12 is lights off). Energy intake (kcal) was calculated from grams of food
consumed during each week. At 14 weeks old, females were fasted for 8-9h during the daytime
(~Zeitgeber time (ZT) 3-12) and euthanized by cervical dislocation and decapitation. Fasting
blood glucose was measured with a glucometer (Accu-Chek Aviva) and body composition was
analyzed with EchoMRI™. At 14 weeks old, females that were heterozygous for PER2::LUC were
not fasted and tissues were collected to analyze bioluminescence rhythms in tissues. Other
methods used for this study are described below.
Experiment 2: ERα agonist treatment of female mice
At 11-12 weeks old, females were ovariectomized and left to recover for a week. Mice
were placed in cages (33 cm × 17 cm × 14 cm) with locked running wheels in light-tight boxes in
12L:12D (250-350 lux, white LEDs). At 12-13 weeks old, mice were implanted with a pellet
(Innovative research, Sarasota, FL) containing either vehicle (control) or PPT (containing either
1.157mg PPT/pellet or 2.55mg PPT/pellet) and left to recover for 1 week. All mice were fed LFD
for the first two weeks. At 13-14 weeks old, LFD was then either continued or mice were
switched to HFD and continued for 2 weeks until the end of the experiment. Body weight and
food consumption were measured weekly at ZT 9-12. At the end of the experiment (15-16
weeks old), some females were fasted from ZT3 to ZT10 and euthanized by cervical dislocation
and decapitation. Fasting blood glucose and body composition were collected. Females
heterozygous for PER2::LUC were not fasted and tissues were collected to analyze
bioluminescence rhythms in tissues.
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Ovariectomy and pellet implant surgeries
Mice in experiment 2 were ovariectomized and implanted with pellets. Females were
anesthetized with inhaled isoflurane and given 5-10 mg/kg subcutaneous ketofen analgesic
(Henry Schein) pre-operatively. A midline skin incision was made on the back followed by two
lateral incisions on the peritoneal wall. PGA absorbable sutures were used to tie the ovaries
(between the ovaries and oviduct) and the ovaries were excised. Peritoneal incisions were
closed with PGA sutures and skin incisions closed with wound clips. Post-operative analgesic (510 mg/kg ketofen, s.c.) was administered once 24 h after surgery and wound clips were
removed 7 days after surgery.
One week after ovariectomy, mice were implanted with either 30-day slow-release lowconcentration (1.157mg/pellet) or high-concentration (2.55mg/pellet) PPT (Tocris Bioscience)
pellets or control pellets. Pellets were made by Innovative Research of America, Sarasota, FL.
We selected the higher dose of PPT of ~4.05 μg·g−1·day−1 because previous studies showed that
PPT concentrations between 0.1 μg·g−1·day−1 and 5 μg·g−1·day−1 were as effective as estradiol
doses of 5 μg·kg−1·day−1 in improving glucose tolerance and insulin sensitivity, increasing energy
expenditure, and protecting OVX mice from diet-induced obesity246,446. A PPT dose of 0.5mg/day
also increased uterine weight, which is a physiological measure of ERα signaling245. In
preliminary experiments, the high-dose PPT pellets caused weight loss in mice, so we included a
low-dose pellet equivalent to 1.84 μg·g−1·day−1 PPT. The pellet was implanted in the dorsal part
of the neck. Post-operative analgesic (5-10 mg/kg ketofen, s.c.) was administered once 24 h
after surgery and wound clips were removed 7 days after surgery. Uterine wet weight was
measured at the end of the experiment as a physiological marker of ERα activation.
Eating Behavior Rhythm Recording and Analysis
Eating behavior was continuously recorded during the last 2 weeks of each experiment
using infrared cameras (HD 48Led 940nm) connected to a Lorex MPX 1080p Security DVR
System. Videos were watched and analyzed in 1 min-bins as previously described389. Individual
days of eating behavior data were then plotted in circular histograms in 10-min bins (Oriana
4.02; Kovach Computing Services, Wales, UK). The mean vector was determined from Rayleigh’s
test. The amplitude of the rhythm was the length of the vector, and the phase was the direction
of the vector. Eating behavior was defined as arrhythmic (eating events were evenly distributed
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across the day) when Rayleigh’s uniformity test p>0.05. If the eating behavior was arrhythmic
then the value of amplitude was 0 and there was no phase.
Locomotor Activity Rhythm Recording and Analysis
Locomotor activity was continuously monitored using passive infrared sensors (Adafruit)
connected to a computer with ClockLab Acquisition software (Actimetrics, Wilmette, IL). In
Experiment 1, locomotor activity was recorded during the 6 weeks of HFD feeding. In
Experiment 2, locomotor activity during the last 6 days of either LFD or HFD feeding were used
to generate activity profiles. Cosinor analysis of activity profiles was performed in Clocklab to
determine the amplitude (half of the peak-to-trough), phase (the timing of the peak of the
rhythm), and mesor (midline Statistic of Rhythm or rhythm-adjusted mean) of the activity
rhythms.
Bioluminescence Recording and Analysis
Heterozygous PER2::LUC female mice were euthanized by cervical dislocation and
decapitation within 1.5h before lights out (ZT10.5-12). Coronal SCN slices (300µm) and explants
of aorta, kidney, liver, lung, soleus muscle, pituitary, spleen, and white adipose tissue (WAT)
were cultured to measure PER2::LUC bioluminescence rhythms as previously described66,394.
Tissue bioluminescence was measured in 10-min intervals with the LumiCycle apparatus
(Actimetrics). Data were smoothed and detrended using LumiCycle Analysis software
(Actimetrics). Phases of bioluminescence expression of each tissue were determined by
analyzing the peak between 12-36h in culture using ClockLab Analysis software (Actimetrics).
Statistical Analysis
For experiment 1, Two-way ANOVA with repeated measures with diet and genotype as
factors was used for all analysis except for Fig 4.4. where unpaired t-tests (two-tailed) was used.
For experiment 2, two-way ANOVA was used for all datasets with diet and treatment type as
factors (Fig. 4.5). Post-hoc Fisher tests were used when interaction terms were significant.
Significance was ascribed at p<0.05.
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Results
ERα KO female mice are susceptible to diet-induced obesity
Consistent with previous studies, we found that ERα KO females rapidly gained weight
(Fig. 4.1A, Table S4.1) and had increased adiposity (Fig. 4.1B, t-test, t=2.08, p<0.001) compared
to ERα WT females after 6 weeks of HFD feeding. Fasting blood glucose at the end of the
experiment was significantly higher in ERα KO females compared to ERα WTs (Fig. S4.1C, t-test,
t=2.08, p<0.001). Calories consumed during HFD feeding was also greater in ERα KO compared
to ERα WT females from the second week of HFD feeding (Fig. 4.1D, Table S4.1)

*

*

*

*

Figure 4. 1. ERα KO mice have exacerbated diet-induced obesity.
Body weights (A) of female ERα WT (green)and ERα KO (red) mice fed low-fat diet (7-8 weeks
old) and then 45% high-fat diet (8-14 weeks old; arrow indicates when high-fat diet was given;
n=22-23/group). Body composition (B) was measured at 14 weeks old to determine adiposity
(n=11-15/group). Fasting blood glucose (C) was measured at 14 weeks old (n =11-15/group).
Total energy intake (D: kcal) was measured during the 6 weeks of high-fat diet feeding (8-14
weeks old; n=17-19/group). Data are mean ±SEM.*p<0.05.
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Daily eating behavior rhythms in ERα KO female mice during HFD feeding
We previously found that circulating estradiol protected the daily rhythm of eating
behavior from disruption by HFD feeding in female mice (Ch. 2). We next sought to determine if
this protection of the eating behavior rhythm in female mice is mediated by ERα. We measured
eating behavior rhythms during LFD and HFD feeding in female ERα WT and ERα KO mice. ERα
WT and ERα KO females had consolidated nighttime eating behavior rhythm during LFD feeding
as indicated by a high amplitude rhythm (Fig. 4.2A: LFD) with a nighttime phase (Fig. 4.2B: LFD).
There was an interaction effect of diet and genotype on the amplitude of the eating
behavior rhythm (Fig. 4.2A, Table S4.2, p= 0.02). Consistent with our prior results, the amplitude
of the eating behavior rhythm was not altered by HFD feeding in ERα WT mice (Fig. 4.2A,
p=0.35). In contrast, the amplitude of the eating rhythm was reduced by HFD feeding compared
to LFD in ERα KO mice (Fig. 4.2A, p=0.008). These data suggest that ERα is necessary to protect
the eating behavior rhythm amplitude from disruption by HFD feeding.
The phases of the eating behavior rhythms were not affected by diet or genotype (Fig.
4.2B, Table S4.2). Both ERα WT and ERα KO mice had reduced feeding event during HFD feeding,
most likely because HFD is more calorically dense than LFD (Fig. 4.2C, Table S4.2, p= 1.72E-8).
There was also an interaction effect of diet and genotype with ERα WT mice having more
feeding events during LFD compared to ERα KO mice (Fig. 4.2C, Table S4.2, p= 0.004). These
data show that estrogen may confer protection of the eating behavior rhythms during HFD
feeding in female mice via ERα.
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Figure 4. 2. Does circulating estradiol protect the daily eating behavior rhythm in females via
ERα signaling during high-fat diet feeding?
Representative actograms of eating behavior in WT mice (green) and KO mice (red) fed LFD for
1 week followed by 6 weeks of HFD feeding. Mean (±SEM) amplitude (A), phase (B) of eating
behavior rhythms and feeding events (C) for WT mice on the last day of LFD and last day of
study (6 weeks of HFD). n=11/group. *p<0.05

Daily locomotor activity rhythms during HFD feeding in ERα KO female mice
During LFD and HFD feeding, female ERα WT (Fig. 4.3A) mice had robust daily rhythms
of nocturnal activity. The amplitude (Fig. 4.3A, Table S4.3, p= 0.006) of activity increased during
HFD feeding in ERα WT mice. Although the amplitude of the locomotor activity rhythm
decreased during HFD feeding in ERα KO mice (Fig. 4.3A, Table S4.3, p= 0.006), the locomotor
activity rhythm amplitude during LFD-feeding (Fig. 4.3A, Table S4.3, p= 0.002) and HFD feeding
(Fig. 4.3A, Table S4.3, p= 2.51E-6) was lower in KO mice compared to WTs. The phases of the
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locomotor activity rhythms were not affected by diet or genotype (Fig. 4.3B, Table S4.3). There
was a main effect of genotype on mesor with of locomotor activity rhythm with ERα KO mice
being lower than ERα WT mice (Fig. 4.3C, Table S4.3, p<0.001).

*

*

Figure 4. 3. The locomotor activity rhythm is disrupted in female ERα KO mice.
Activity rhythms of WT (green) and KO (red) female mice was analyzed. Mice were fed LFD for
1 week and HFD for 6 weeks. Mean (±SEM) activity profiles (B), amplitude (C), mesor (D), and
phase (E) of locomotor activity rhythms during LFD feeding (days 2-7) and HFD feeding (days
2-41). n=11-15/group. *p<0.05

Circadian organization is disrupted by HFD feeding in ERα KO mice
We measured PERIOD2::LUCIFERASE bioluminescence in tissues cultured from female
ERα WT and ERα KO mice (Fig. 4.4). Tissues were cultured after 6 weeks of HFD feeding. We
found that the phases of the PER2::LUC rhythms in the aorta, kidney, lung, muscle, pituitary
SCN, spleen, and WAT did not differ between ERα WT and ERα KO mice (Fig. 4.4). The phase of
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the liver PER2::LUC rhythm was advanced (~4h) in ERα KO females compared to ERα WTs (Fig.
4.4, t-test, t=2.18, p<0.001). These data show that ERα regulates the phase of the liver circadian
clock during HFD feeding.
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Figure 4. 4. ERα regulates the response of the liver circadian clock to HFD feeding.
Heterozygous PER2::LUC ERα WT (green) and ERα KO (red) female mice were fed high-fat diet
for 6 weeks. Tissues were cultured and bioluminescence was measured. The mean phases
(±SEM) of the peaks of the bioluminescence rhythms were plotted relative to last lights on.
The white and black bars indicate light and dark respectively. Number of rhythmic
samples/number of samples cultured is shown for each tissue. *p<0.001.
Selective activation of ERα protects ovariectomized mice from diet-induced obesity
Next, we aimed to determine if ERα activation alone is sufficient to protect female mice
from diet-induced obesity. We analyzed body weight (Fig. 4.5A) and adiposity (Fig. 4.5B) in
female C57BL/6J mice that were OVX and implanted with either control pellets or with pellets
containing low-dose or high-dose PPT, which is a selective ERα agonist. Consistent with prior
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studies, HFD-fed OVX females implanted with control pellets rapidly gained weight compared to
all other groups (Fig. 4.5A red circles, Table S4.4). HFD-fed low-dose PPT mice also rapidly gained
weight compared to all other groups apart from HFD-fed control mice (Fig. 4.5A red triangle,
Table S4.4). The high dose of PPT completely inhibited diet-induced obesity since the body
weight of LFD-fed and HFD-fed mice in the high-dose PPT group do not differ (Fig. 4.5A square,
Table S4.4). Our data showed that females in the high dose PPT group fed LFD lost weight and
displayed clinical signs of sickness including hunched posture (Fig. 4.5A). Thus, the high-dose PPT
results should be interpreted with caution as the mice may have been unhealthy. The low-dose
PPT group maintained normal body weights and appeared healthy, but this dose was too low to
prevent diet-induced obesity
HFD-fed control mice also had greater adiposity than every other group (Fig. 4.5B, Table
S4.4). HFD-fed low-dose PPT mice had the next highest adiposity amongst the 6 groups (Fig.
4.5B, Table S4.4). Adiposity did not differ amongst the 3 LFD-fed groups (Fig. 4.5B, Table S4.4).
HFD-fed high-dose PPT mice also maintained similar adiposity to all the LFD-fed groups (Fig.
4.5B, Table S4.4). Blood glucose increased during HFD feeding compared to LFD groups in both
control and low PPT dose groups (Fig. 4.5C, Table S4.4). In the high-dose PPT group, blood
glucose did not differ between HFD and LFD-fed counterparts (Fig. 4.5C, Table S4.4). Blood
glucose did not differ in the LFD groups regardless of treatment (Fig 4.5 C, Table S4.4).
Cumulative food intake differed as a result of diet, treatment, and there was also an
interaction of diet and treatment (Fig 4.5D, Table S4.4). Mice in each treatment consumed more
calories when fed HFD compared to mice in the LFD groups (Fig 4.5D, Table S4.4, p= 2.70E-17).
HFD-fed control mice also consumed more calories than did either HFD-fed low-dose PPT (Fig
4.5D, Table S4.4, p= 3.93E-4) and HFD-fed high-dose PPT mice (Fig 4.5D, Table S4.4, p= 0.008).
There was no difference in calories consumed amongst the LFD groups (Fig 4.5D, Table S4.4).
Uterine size is an in vivo physiological marker of ERα signaling so we measured uterine
weight at the end of the experiment. There was only an effect of treatment on uterine size (Fig.
4.5E, Table S4.4). Uteruses from mice in high PPT group were larger, ~2.5x more, than that of
the low-dose PPT group (Fig. 4.5E, Table S4.4, p= 5.41E-19) and ~4.5x more than that of control
females (Fig. 4.5E, Table S4.4, p= 3.00E-21). Uterine weight did not differ between low-dose PPT
mice and controls (Fig. 4.5E, Table S4.4, p= 0.09).

93

*

*

*

*

*

Figure 4. 5. Effects of ERα activation on diet-induced obesity.
C57BL/6J mice were ovariectomized and implanted with pellets containing either control
vehicle (circle), low dose PPT (triangle) or high dose PPT (square). Mice were fed LFD for 2
weeks followed by 2 weeks of either 10% LFD (blue) or 45% HFD (red). Body weights (A);
arrow indicates when diet was changed to HFD or continued as LFD; n=3-12/group.
Cumulative food intake (B) for the last 2 weeks of the experiment (when the mice were
placed on respective diets); n=2-11/group. Fasting blood glucose (C) was measured at 15-16
weeks old at the end of the study (n =1-6/group). Body composition (D) was measured at 1516 weeks old to determine adiposity (n=1-6/group). Uterine weight (E) collected at the end of
the experiment; n=3-12/group.
ERα selective activation may protect eating rhythm from HFD-induced disruption in female mice
The amplitude of the eating behavior rhythm was affected by diet and treatment, but
there was no significant interaction (Table S4.5). The amplitude of the eating behavior rhythm
was decreased in HFD-fed mice compared to LFD-fed mice (Fig. 4.6A, Table S4.5, p= 7.75E-4).
HFD-fed high-dose PPT mice had a greater eating rhythm amplitude than HFD-fed control mice
(Fig. 4.6A, Table S4.5, p= 0.05). High-dose PPT mice fed LFD had higher eating rhythm amplitude
than both control (Fig. 4.6A, Table S4.5, p= 0.002) and low-dose PPT mice (Fig. 4.6A, Table S4.5,
p= 6.20E-4) fed LFD. The phase of the eating behavior rhythm was not affected by diet or
treatment (Fig. 4.6B, Table S4.5). Mice in all HFD groups had reduced feeding events compared
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to corresponding LFD-fed groups (Fig. 4.6C, Table S4.5, p= 1.82E-9). Mice in all HFD-fed groups
had similar number of feeding events (Fig. 4.6C, Table S4.5) while feeding events was only
increased in the LFD-fed high-dose PPT compared to both control (Fig. 4.6C, Table S4.5, p=
0.001) and low-dose PPT groups (Fig. 4.6C, Table S4.5, p=0.01).

*

*
*

*

*

Figure 4. 6. Effects of ERα activation on daily rhythms of eating behavior in female mice.
Mean (±SEM) amplitude (A), phase (B) of eating behavior rhythms and feeding events (C)
for OVX females in the control, low-PPT and high-PPT pellet groups are analyzed from
feeding behavior rhythm on the last day of the study. Mice maintained on LFD for the study
duration (blue) vs. those fed 2 weeks of HFD after initial 2 weeks of LFD (red). n=2-7/group.
*p<0.05
Selective activation of ERα is sufficient to protect daily rhythms of locomotor behavior from HFDinduced disruption in female mice.
Next, we sought to determine the effect of HFD on daily locomotor activity rhythm of
OVX mice that were implanted with a pellet with the ERα selective agonist PPT (Fig. 4.7). There
was an effect of treatment and an interaction effect on amplitude of eating rhythm (Fig. 4.7A,
Table S4.6). HFD-fed high-dose PPT mice had higher locomotor activity rhythm compared to
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HFD-fed control (Fig. 4.7A, Table S4.6, p<0.001), and low-dose PPT mice (Fig. 4.7A, Table S4.6,
p<0.001). There was no difference in the amplitude of the activity rhythm between LFD and
HFD-fed mice in the control groups (Fig. 4.7A, Table S4.6, p=0.55) and low-dose PPT groups (Fig.
4.7A, Table S4.6, p=0.09).
There was an interaction effect in the phase of locomotor rhythm (Fig. 4.7B, Table S4.6).
There was a phase delay during HFD-feeding in control mice (Fig. 4.7B, Table S4.6, p=0.03) while
there was a phase advance during HFD-feeding in high-dose PPT mice (Fig. 4.7B, Table S4.6,
p=0.02) compared to LFD-fed counterparts. HFD-fed high-dose PPT mice also had an advanced
phase compared to low-dose PPT groups (Fig. 4.7B, Table S4.6, p=0.006). The phase of low-dose
PPT mice on both LFD and HFD did not differ and was comparable to control mice (Fig. 4.7B,
Table S4.6).
There was an effect of diet and treatment on mesor of locomotor activity rhythm (Fig.
4.7C, Table S4.6). Mesor differed between HFD-fed high-dose PPT mice and HFD-fed control
mice (Fig. 4.7C, Table S4.6, p= 0.007). Mesor was not affected by diet in the control (Fig. 4.7A,
Table S4.6, p= 0.10) or low-dose PPT groups (Fig. 4.7A, Table S4.6, p= 0.36).
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Figure 4. 7. Effects of ERα activation on daily rhythms of locomotor activity in female mice.
Activity rhythms of OVX females implanted with either control, low-PPT or high-PPT pellet are
analyzed from feeding behavior rhythm on the last week of the study. Mice maintained on
LFD for the study duration (blue) vs. those fed 2 weeks of HFD after initial 2 weeks of LFD
(red). n=11/group. *p<0.05

Tissue circadian organization is protected against HFD-induced disruption via ERα activation
We measured PERIOD2::LUCIFERASE bioluminescence in tissues cultured from OVX
female mice implanted either with control or PPT (low- and high-dose) pellets (Fig. 4.8) and fed
LFD or HFD. There were no significant effects of diet or treatment on PER2::LUC rhythms in the
aorta, kidney, lung, muscle, SCN, and spleen (Table S4.7). There was a main effect of PPT
treatment on the phase of the liver rhythm. There appears to be a dose-dependent delay of the
liver rhythm with PPT treatment. There was also a main effect of PPT treatment on the phase of
the WAT (Table S4.7). High dose PPT advanced the phase of the WAT rhythm. These results
suggest that ERα activation can regulate the phase of the liver and WAT clocks.
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Figure 4. 8. Effects of ERα activation on circadian organization.
Heterozygous PER2::LUC were OVX-ed and implanted with either control (circle), low PPT
(triangle) or high PPT (square) pellet. Mice were fed either LFD (blue) or HFD (red) for 2
weeks. Tissues were cultured and bioluminescence was measured. The mean phases (±SEM)
of the peaks of the bioluminescence rhythms were plotted relative to last lights on. The white
and black bars indicate light and dark respectively. n=1-6/group. *p<0.05
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Discussion
Previous studies have shown that estrogens protect female mice from metabolic
dysfunction 90,239-242. In this study, we investigated the estrogen signaling mechanism that
protects daily rhythms in females from disruption by HFD feeding. Since these previous studies
showed that ERα mediates most of the metabolic protection in female mice90,239-242, I aimed to
determine if estrogen signaling via ERα is necessary and sufficient to protect rhythms in female
mice from the detrimental effects of HFD-feeding.
We first studied global ERα KO mice to determine if ERα is necessary to regulate daily
rhythms during HFD feeding. Our results aligned with previously reported studies showing that
female global ERα KO mice were susceptible to diet-induced obesity, unlike WT female mice
that are resistant. The eating behavior rhythm was also disrupted by HFD feeding in female ERα
KO mice but not in WT mice (Fig. 4.2). We found that the disruption of the eating behavior
rhythm by HFD in ERα KO was similar to our prior studies in OVX mice (Ch. 2) and in male
mice388,389,451. These data demonstrate that ERα is necessary for estrogen regulation of the
eating behavior rhythm in female mice during HFD feeding.
We also found that the locomotor activity rhythm was dampened in ERα KO mice
compared to ERα WT mice, on both LFD and HFD. The effect was more pronounced in ERα KO
during HFD feeding (Fig. 4.3). This is consistent with previously reports of activity in ERα KO mice
during HFD intake239-242,445.
ERα KO females also had an advanced phase of the liver clock compared to ERα WT mice
during HFD feeding, similar to our prior findings in OVX mice (Ch 2) and in male mice. These data
indicate that ERα is required to protect the liver circadian clock from disruption by HFD.
We next examined if selective activation of ERα signaling using the ERα agonist PPT was
sufficient to protect daily rhythms during HFD feeding. The results of this study are so far
inconclusive. When ovariectomized females were treated with high-dose PPT, they were
resistant to diet-induced obesity, similar to gonadally intact female mice, but they appeared
unhealthy. Thus, we also studied OVX females treated with low-dose PPT. The low-dose PPT
group had a slight inhibition of diet-induced obesity, but still had marked weight gain and
adiposity. While these mice appeared healthy, we postulate that the PPT dose did not
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sufficiently activate ERα signaling to regulate metabolism. The uterine weights of females
treated with low-dose PPT were only slightly greater than mice in the control mice, which have
virtually no circulating estrogens. These data suggest that the low-dose PPT treatment only
slightly activated ERα signaling systemically. Another experiment should be performed at an
intermediate dose of PPT to achieve greater activation of ERα signaling but avoid the negative
health consequences of high PPT doses.
Based on the our data collected thus far, there seems to be a dose dependent effect of
PPT on uterine weight, liver PER2::LUC rhythm phase, and adiposity and food intake during HFD
feeding. The low-dose PPT mice have an intermediate effect compared to control and high-dose
PPT mice. However, the data should be interpreted cautiously since the high-dose PPT made the
mice sickly (especially mice in the LFD group) and most of these mice lost weight during the
experiment. In addition, most mice in the HFD-fed high-dose PPT group shredded their food
which accounts for the low sample size in eating behavior rhythm analysis. It is also interesting
to note that water consumption (not measured, but water bottles had to be filled weekly, as
opposed to every few weeks) was greatly increased in the high-dose PPT group, as explored in
other studies of the role of ERs in fluid intake452.
Based on our results so far, estrogen signaling via ERα is necessary for protection of
daily rhythms of eating behavior, locomotor activity, and the liver molecular clock in female
mice from the effects of HFD feeding. We cannot yet determine whether ERα signaling is
sufficient for protection of these daily rhythms. The high-dose PPT caused the mice to lose
weight and become sickly during LFD feeding and the low-dose PPT did not effectively activate
ERα signaling since the uteruses were small and the females were susceptible to diet-induced
obesity. Future studies should investigate the effects of an intermediate dose of PPT that
confers the protection against HFD-induced obesity on daily rhythms in female mice.
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Chapter 4 Supplemental Material
Table S4. 1. Repeated measures two-way ANOVA analysis of body weight and food intake in
female ERα WT and ERα KO mice fed HFD.
Repeated Measures two-way ANOVA
Body weight

Food Intake

Genotype

F= 286.92, p= 1.22E-11*

Time

F= 948.39, p= 1.14E-15*

Genotype*Time

F= 506.45, p= 1.54E-13*

Genotype

F= 42.61, p= 2.82E-5*

Time

F= 3231.84, p= 2.93E-10*

Genotype*Time

F= 14.67, p= 0.014*

Table S4. 2. Repeated measures two-way ANOVA analysis of eating behavior rhythms in
female ERα WT and ERα KO mice fed LFD and then HFD.
Eating behavior
parameter

Repeated Measures two-way ANOVA
Diet

Genotype

Diet*Genotype

Amplitude

F= 5.64, p= 0.04*

F= 0.24, p= 0.63

F= 7.66, p= 0.02*

Phase

F= 0.12, p= 0.74

F= 1.28, p= 0.30

F= 0.83, p= 0.40

Number of
events

F= 585.13, p= 3.32E10*

F= 3.44, p= 0.09

F= 8.84, p= 0.014*

Table S4. 3. Repeated measures two-way ANOVA analysis of locomotor activity rhythms in
female ERα WT and ERα KO mice fed LFD and then HFD.
Activity rhythm
parameter

Repeated measures two-way ANOVA
Diet

Genotype

Diet*Genotype

Amplitude

F= 2.24, p= 0.16

F= 49.89, p= 3.44E-5*

F= 31.62, p= 2.20E-4*

Phase

F= 4.75, p= 0.05*

F= 0.37, p= 0.56

F= 4.19, p= 0.07

Mesor

F= 0.007, p= 0.09

F=20.16, p= 0.001*

F=13.26, p= 0.005*
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Table S4. 4. Two-way ANOVA analysis of metabolic factors and uterine weight in OVX female
mice implanted with control, low PPT, or high PPT pellets and fed LFD or HFD.
Body weight during the last week and total calorie intake for the 2 weeks of experiment
analyzed. The factors for two-way ANOVA were diet and treatment. *p<0.05
Two-way ANOVA
Diet
Body Weight
Cumulative
Food Intake

Treatment

Diet*Treatment

F= 22.55, p= 1.88E-5*

F= 23.24, p= 8.75E-8*

F= 3.73, p=0.03*

F= 118.57, p= 2.17E-13*

F= 6.58, p= 0.003*

F= 45.81, p= 0.03*

Blood Glucose

F= 1.29, p= 0.27

F= 3.66, p= 0.04*

F= 1.33, p= 0.28

Adiposity

F= 13.22, p= 0.001*

F= 6.20, p= 0.007*

F= 5.59, p= 0.01*

Uterus weight

F= 2.20, p= 0.15

F= 158.57, p= 0*

F= 1.05, p= 0.36

Table S4. 5. Two-way ANOVA analysis of eating behavior rhythms in OVX female mice
implanted with control, low PPT, or high PPT pellets and fed LFD or HFD.
Eating behavior
parameter

Two-way ANOVA
Diet

Treatment

Diet*Treatment

Amplitude

F= 13.26, p= 0.001*

F=8.26, p= 0.001*

F= 1.34, p= 0.28

Phase

F= 0.11, p= 0.74

F= 0.51, p= 0.61

F= 0.02, p= 0.99

Number of Events

F= 72.21, p< 0.001*

F=2.06, p= 0.15

F= 5.08, p= 0.01*

Table S4. 6. Two-way ANOVA analysis of locomotor activity rhythms in OVX female mice
implanted with control, low PPT, or high PPT pellets and fed LFD or HFD.
Activity rhythm
parameter

Two-way ANOVA
Diet

Treatment

Diet*Treatment

Amplitude

F= 3.86, p= 0.06

F= 15.75, p<0.001*

F= 7.11, p= 0.003*

Phase

F= 0.93, p= 0.34

F= 1.49, p= 0.24

F= 5.54, p= 0.009*

Mesor

F= 6.05, p= 0.02

F= 5.89, p= 0.007*

F= 0.47, p= 0.63
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Table S4. 7. Two-way ANOVA analysis of phases of PER2::LUC rhythms from tissues explanted
from OVX female mice implanted with control, low PPT, or high PPT pellets and fed LFD or
HFD.
Tissue
Phase

Two-way ANOVA
Treatment

Diet

Diet*Treatment

Aorta

F= 0.01, p= 0.94

F= 0.06, p= 0.94

F= 0.04, p= 0.96

Kidney

F= 0.16, p= 0.69

F= 0.05, p= 0.95

F= 0.86, p= 0.44

Liver

F= 0.40, p= 0.53

F= 5.66, p= 0.01*

F= 0.18, p= 0.83

Lung

F= 1.74, p= 0.20

F= 0.61, p= 0.40

F= 0.39, p= 0.68

Muscle

F= 0.41, p= 0.53

F= 1.37, p= 0.28

F= 0.32, p= 0.73

Pituitary

F= 2.93, p= 0.10

F= 9.14, p= 0.002*

F= 2.38, p= 0.12

SCN

F= 9.05, p= 0.008*

F= 0.61, p= 0.55

F= 1.63, p= 0.22

Spleen

F= 0.21, p= 0.65

F= 1.64, p= 0.22

F= 0.48, p= 0.63

WAT

F= 0.27, p= 0.61

F= 7.41, p= 0.004*

F= 0.04, p= 0.96
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CHAPTER 5: DISCUSSION
5.1 Summary of research preceding my dissertation
More than 13% of adults (600 million) in the world453 and 42% of adults in the U.S. are
obese454. Increased caloric intake from foods high in fats and sugars and decreased physical
activity are well-documented causes of obesity375,455. Studies in the last 15 years have
established that the circadian timing system also regulates obesity400,456. The majority of the
mechanistic studies linking circadian rhythms to obesity and metabolic dysfunction were
performed in male mice. The goal of my dissertation was to study the interplay between
circadian rhythms and obesity in female mice.
The mammalian circadian system is composed of a main clock located in the
suprachiasmatic nucleus (SCN) and multiple tissue clocks. The circadian timekeeping mechanism
in cells is a transcription-translation feedback loop (TTFL) that takes approximately 24 hours to
complete one cycle. The first studies that linked circadian rhythms to obesity were performed in
mice with mutations in genes that are components of the TTFL456,457. For example, the Turek lab
found that ClockΔ19 mutant mice had increased adiposity compared to wild-type mice456. This
study was performed only in males.
In these early studies, it also became clear that the daily rhythm of eating was an
important factor in the link between the circadian system and obesity. In male mice, high-fat
diet (HFD) consumption increased obesity and its comorbidities. The Bass lab and others showed
that the eating rhythm of male mice became arrhythmic or low amplitude during HFD
feeding388,389,399. The Turek lab then showed that the time of eating determined whether a
mouse became obese on HFD400. They fed male mice HFD either only during the daytime or only
during the nighttime. The daytime fed mice gained significantly more weight than the nighttime
fed mice. Several labs then went on to show that time-restricted feeding (TRF) of HFD is a
strategy to reduce obesity in male mice396,399,403,404.
Our lab was the first to show that HFD feeding disrupts circadian organization in male
mice. HFD feeding caused a phase advance (~5hrs) in the liver molecular clock389. Other labs
later showed that many liver metabolites such as lysine, cytochrome P450 monooxygenase
(Cyp2a5), and arachidonate were also phase advanced by HFD feeding in males458.
Our lab was also the first to study the link between circadian rhythms and HFD-induced
obesity in female mice. Female C57BL/6J mice are protected from diet-induced obesity and the
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detrimental effects of HFD feeding on their daily rhythms232,355,459. Female mice maintained a
robust nocturnal feeding behavior rhythm and a properly phased liver clock on HFD similar to
when they were fed low-fat diet (LFD). Ovariectomy, which causes females to have virtually no
circulating estrogens, made females susceptible to diet-induced obesity just like male mice232.
Ovariectomized female mice also had low-amplitude or arrhythmic eating rhythms and had an
advanced liver clock (~4hrs) during HFD feeding, like male mice355. These data suggested that
estrogen could protect females from diet-induced obesity by protecting their rhythms from
disruption by HFD feeding.
These findings in female mice have translational relevance to women. Women lacking
circulating estrogens are more susceptible to obesity-related disorders than those with
estrogens210. Several studies have shown that hormonal replacement therapy, such as estradiol
and progesterone treatment, reduces the risk of cardiovascular disease and metabolic syndrome
in postmenopausal women225-228. Thus, it is important to study the role of estrogen in regulating
circadian rhythms and obesity since this could be applied to future therapies in women.
The goal of this dissertation was to study the link between the circadian system and
diet-induced obesity in female mice. I first sought to determine if circulating estrogens are
indeed responsible for conferring protection in females against HFD-induced metabolic and
circadian disruption (Ch 2). I then worked to identify the signaling mechanism by which this
protection by estrogen is conferred (Ch 3,4).
5.2 Summary of dissertation research
Chapter 2
First, we examined the role of 17β-estradiol (E2) in mediating protection of daily
rhythms in female mice. We showed that replacement of physiological levels of circulating
estradiol to ovariectomized mice protected them from the detrimental effects of HFD feeding.
Consistent with previous studies232,235,238, circulating exogenous estrogens prevented OVX
females from developing diet-induced obesity (Ch. 2). It was already known that male mice
become obese on HFD partly because of their low amplitude/arrhythmic eating behavior
rhythm. Enforcing a robust eating rhythm by restricting HFD feeding to the proper time of the
day (night-time only feeding) protected male mice from DIO396. We showed that the eating
rhythm contributes to diet-induced obesity in OVX females too. Our results show that TRF (12h
night-only feeding) HFD feeding of OVX mice partially inhibited diet-induced obesity. Glucose
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tolerance was also improved in the TRF group compared to ad-libitum group. However, the
phase of the liver circadian clock remained advanced during TRF, similar to the ad libitum-HFD
fed OVX females. This suggests that diet, but not the timing of food intake, was responsible for
circadian disruption of the liver molecular clock. Perhaps we did not see the same level of
protection against diet-induced obesity from TRF as we did in the OVX mice treated with E2
because TRF was not able to rescue the advanced phase of the liver clock in the OVX females.
Our results support that TRF might be an effective tool in combating some of the negative
effects of HFD feeding in women that lack circulating estrogens396,403,460.
Previous studies have shown that OVX reduces total activity in female mice while E2
supplementation increases both locomotor and wheel-running activity levels242,248,355,461,359,.
Consistent with previous studies we found that while the amplitude of the activity rhythm was
reduced in OVX mice, it remained similar during LFD and HFD feeding in this group. In contrast,
treatment of OVX mice with a physiological dose of circulating E2 helped them maintain a high
amplitude activity rhythm during LFD which increased during HFD feeding. This may be a
mechanism by which these females are resistant to DIO by increasing energy expenditure on
HFD462,463.
We also examined the effect of circulating estradiol on the organization of circadian
clocks in central and peripheral tissues of OVX mice. Rhythms of circadian gene expression are
altered by HFD feeding in the liver of male mice388,458 specifically with a phase advance of ~5h in
PER2::LUC rhythm after 1 week of HFD feeding389. This results in circadian misalignment of the
liver clock relative to the other tissues. In contrast, the phase of the liver clock was not affected
by HFD feeding in gonadally intact female C57BL6J mice355. Our result here shows that the liver
PER2::LUC rhythm was advanced ~4.5hrs in OVX females compared to OVX females that
received a physiological dose of E2. This result shows suggests that estrogens inhibit the effect
of HFD feeding on the liver circadian clock in female mice.
Chapter 3
OVX female mice fed HFD have reduced amplitudes of eating behavior rhythms and
have a phase advance of their liver clock, and estradiol replacement inhibits these detrimental
effects451. Estradiol is known to signal via various estrogen receptors (ERs) to prevent females
from developing diet-induced obesity and the metabolic syndrome235,378. We next examined the
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potential estrogen signaling mechanisms that regulate circadian organization, or the temporal
relationship between tissue clocks in the body.
Loss of ERα signaling caused circadian misalignment in the phase of the liver clock such
that male and female ERα KO mice had advanced PER2::LUC rhythms. The phase of the liver
clock was not altered in ERβ or GPER1 KO mice. Although ERα and GPER are both expressed in
the mouse liver, ERα is more highly expressed, which may explain why we observe an effect on
liver phase in ERαKO mice, but not in the other KO mice. 115. The period of the liver was affected
by GPER1 KO with longer periods in GPER KO mice compared to WTs. This study shows that the
phase of the liver is modulated via ERα while the period of the liver PER2 rhythm is regulated by
GPER1.
We found that the phase of the SCN is affected by both ERα and ERβ that act in opposite
directions. Loss of ERα signaling caused an advanced phase in SCN explants in both males and
females while ERβ KO caused a delay in the phases of the SCN explants in both males and
female mice. This implies that ERα and ERβ in the SCN work antagonistically to maintain the
phase of the SCN clock. This result was unexpected because our previous study (Ch 2) showed
that E2 signaling had no effect on the phase of PER2::LUC rhythms in SCN explants in females
fed HFD. The main difference between these studies is that the mice were fed HFD in that study
(Ch 2) and low-fat chow in this study.
Overall, our results show that ERα, ERβ, and GPER1 have subtle, tissue-specific effects
on regulating the circadian timekeeping mechanisms in the liver and SCN in male and female
mice.
Chapter 4
E2 protects daily rhythms of eating behavior, locomotor activity and liver circadian
rhythms from HFD-induced disruption in OVX mice355 (Ch. 2). We next wanted to investigate the
mechanism by which E2 mediates its protective effects during HFD feeding in females. Previous
studies using mice lacking whole-body ERα showed that ERα is necessary to prevent diet-indued
obesity, insulin resistance, and lipid accumulation in the liver during HFD feeding239,240. ERα KO
mice also weigh more and have reduced wheel-running activity than wild-type mice90,239,242,248.
ERα has therefore been shown to be the receptor via which estrogen mediates most of its
metabolic-related protective effects225-228,239,464. It is important to note that ERα KO mice have
elevated circulating estrogen levels (~3-10x the WT levels)465,466 but still show these detrimental
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effects of diet-induced obesity, thus highlighting the importance of ERα signaling. Propyl
pyrazole triol, PPT, like estradiol treatment, has been shown to protect mice from diet-induced
obesity, and to increase locomotor activity and uterine weight245,246,446-448. We tested whether
ERα was necessary and sufficient to protect daily rhythms in female mice from HFD induced
disruption using selective ERα inactivation using whole-body ERα KO mice and selective
activation using the ERα agonist, PPT.
Our preliminary results are consistent with previous studies that ERα KO mice become
obese, have more adipose tissues and fasting glucose, and consumed more calories compared
to WT mice during HFD feeding (Ch. 4)176,239,242,252,467. Consistent with our previous studies, the
amplitude of the eating behavior rhythm was not affected by HFD feeding in WT females, while
HFD feeding reduced the amplitude of the feeding rhythm in ERα KO mice. While these data
suggest that ERα may regulate the eating behavior rhythm, this disruption was not as severe as
what we see in OVX females. We know E2 levels are higher in ERα KO mice compared to WTs,
which may result in non-physiological over-activation of other ERs465,466,468. Perhaps there is a
compensatory mechanism for the protection of the eating rhythm from E2 stimulation of ERβ or
GPER1 in these ERα KO mice compared to our data in OVX mice. To avoid detrimental effects of
whole-body ERα KO, we could use ERα antagonists such as methyl-piperidino-pyrazole (MPP) or
conditional ERα KO mice in future experiments.
ERα KO mice had reduced amplitudes of locomotor activity rhythms compared to WT
mice even during LFD. During HFD feeding, the amplitude of the locomotor activity rhythm
increased in WT mice but reduced in ERα KO mice. The mesor of the locomotor activity rhythm
was also reduced in ERα KO mice compared to WTs even during LFD feeding. Previous studies
have shown that the liver is the first tissue whose PER2::LUC molecular rhythm is affected by
HFD causing a ~5hr phase advance in both males and OVX females fed HFD (also see Ch. 2)355,389.
Further investigation (Ch. 3) shows that male and female ERαKO mice have an advanced
PER2::LUC phase in their liver during baseline condition compared to their WT counterparts (by
~0.7h). The phase of the liver PER2::LUC rhythm was further advanced during HFD-feeding (Ch.
4) by ~4h in ERα KO female mice compared to WT female mice. This advanced liver phase is
equivalent to the effect of HFD feeding on the liver clock in OVX females suggesting that E2
signals via ERα to protect the phase of the liver circadian clock during HFD feeding.
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Next, we used OVX female mice implanted with the ERα agonist, PPT, to test the
sufficiency of ERα signaling alone in rescuing the diet-induced obesity phenotype and the
detrimental effects of HFD on daily rhythms. Consistent with previous data (Ch. 2), our
preliminary results show that selective activation of ERα with high-dose PPT (~4.05 μg·g−1·day−1)
protects OVX mice from DIO and high fasting glucose. Uterine weight is a physiological marker of
ERα signaling as this causes the uterus to become fluid filled466,469. Uterine weight in the lowdose PPT group (1.84 μg·g−1·day−1 PPT) was similar to that of control OVX mice as this dose did
not cause uterine weight to increase. In contrast, uterus weight increased (~4x) in high-dose PPT
mice compared to control OVX mice showing that PPT activated systemic ERα signaling at this
does. These results indicate that selective activation of ERα does protect female mice from
detrimental effect of HFD feeding but the only at the high dose.
Although the amplitude of the eating rhythm during HFD feeding was higher in the highdose PPT mice compared to control OVX mice (Ch. 4), it was not comparable to our data using
E2 in OVX mice (Ch. 2). Although there was also no difference in the phase of eating behavior
rhythm, the feeding events during HFD were reduced with high-PPT dose treatment compared
to control mice. Taken together, these results indicate that although PPT protects the eating
rhythm, it does this only at a very high dose. Thus, ERα may not be the receptor that protects
the eating behavior rhythm in female mice or it may work together with another ER to confer
this protection. A previous study has shown that selective activation of ERα with PPT makes the
phase of wheel running activity earlier while increasing the amplitude of activity248. This is
similar to our result in this study where we see an increased amplitude and earlier phase with
our high-dose PPT during HFD feeding compared to the control OVX mice (Ch. 4). We also
observed an increased mesor during HFD feeding in high-dose PPT group compared to control
mice. Just like various parameters of the activity rhythm ire controlled by different ERs248,
protection of the feeding rhythm (phase and amplitude) by estrogens may be as a result of
combined signaling mechanism of different ERs.
We also examined circadian organization in tissues explanted from control OVX
PER2::LUC females or OVX females treated with PPT. Consistent with our previous result (Ch. 2),
OVX causes an advance in the liver clock (Ch. 4). PPT treatment delayed the clock in a dosedependent manner (Ch. 4) showing that ERα signaling does indeed protect molecular circadian
organization in the liver from HFD-induced dysregulation.
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Although E2 is the most potent activator of ERα, other circulating estrogens bind and
activate ERα470. Although E1 and E3 have lower affinity for ERα compared to ERβ, E1 is easily
metabolized to E2 and thus acts as a prohormone for estradiol69,471. E3 on the other hand cannot
be metabolized to E2 and can act as an antiestrogen in the presence of E2472. Phytoestrogens
inthe environment, such as genistein, can also activate ERα, although at a lower level compared
to ERβ 473-475. Selective estrogen receptor modulators (SERMs) such as tamoxifen can also
activate ERα and inhibit or stimulate estrogenic action in a tissue dependent manner476.
Phytoestrogens and SERMs are useful for treating menopause symptoms such as hot flashes and
osteoporosis and help reduce cholesterol and heart diseases, similar to estradiol replacement
therapy. A study showed that genistein not only protects female mice from HFD-induced dietinduced obesity, it also increases expression of circadian clock genes in the hypothalamus477.
Raloxifen, a SERM that has antiestrogenic action in the uterus, shortens the period of the
PER2::LUC expression in the mousee uterus in the presence of E2367. All these ER ligands add
complexities to the mechanism involved in this ERα mediated protective effect seen with female
mice circadian rhythms.

5.3 Working hypothesis
I have synthesized my studies into a working hypothesis (Fig. 5.1). The SCN receives
information about the light-dark cycle via the retinohypothalamic tract and synchronizes the
phases of the clocks in other parts of the brain and body, including brain regions that regulate
energy balance such as the VMH, ARC, PVN and NTS. I hypothesize that the site that regulates
eating behavior rhythm is downstream of the SCN because in our studies, HFD feeding does not
alter the phase of the SCN PER2::LUC rhythm, even though it alters the eating rhythm. I
hypothesize that the site that directly controls the eating rhythm is in the ARC or PVN because
of their established roles in controlling food intake478,479. The SCN could coordinate the eating
rhythm by either sending direct SCN neural projections to the ARC and PVN, or via the release of
AVP 191,192,480.
I hypothesize that circulating estrogens (and ERα agonists) bind to ERα in the ARC, PVN,
VMH, or NTS to regulate the eating rhythm. These are ERα expressing brain regions that
regulate energy balance 481-483. During HFD feeding, levels of hormones involved in feeding
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control, such as CCK, GLP-1 and OXM, increase. These peptide hormones have receptors in the
ARC, PVN, VMH and NTS304,319-321,329. Together these brain regions could act synergistically or any
one of these brain regions could be responsible for the control of eating behavior rhythm.
It is most likely that the eating rhythm is the primary mechanism that regulates the
phase of the liver rhythm. This is possible since previous studies have shown that the liver clock
entrains to feeding time389,484. We propose that HFD-induced disrupted eating rhythm in females
lacking circulating E2 then leads to the advanced liver clock. It has been reported that OXM, a
satiety hormone, or glucagon may mediate the ability of meal timing to regulate the phase of
the liver clock. 485. It was found that OXM binds glucagon receptors and shifts Per expression in
the liver, either a phase advance or delay depending on the time of administration485,486. Thus, I
propose that HFD alters the circadian clock in a brain region controlling the eating rhythm, and
the altered eating rhythm then affects OXM to alter the phase of the liver clock.

Figure 5. 1. Proposed model for ligand mediated protection of eating rhythm and liver
molecular clock via ERα activation during HFD feeding in female mice.
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5.4 Future studies
I believe there are 3 main questions that can be investigated next. These are described below.
1. Where is E2 functioning to protect daily rhythms from disruption by HFD in female mice?
We see two striking protective effects of E2, on the daily rhythm of eating
behavior and on the phase of the liver clock. The time of eating can control the phase of
the liver clock, so E2 could have a direct effect on eating, which then indirectly changes
the liver clock. On the other hand, E2 could separately control each rhythm.
The eating rhythm is disrupted in SCN-lesioned rodents407. Therefore, E2 could act
in the SCN or downstream of the SCN to regulate the eating behavior rhythm during HFD
feeding. In our experiments (Ch 2), we found that the eating behavior rhythm, but not
the SCN PER2::LUC rhythm, was disrupted in HFD-fed OVX females. Based on these
findings, we hypothesize that E2 does not regulate the eating rhythm via the SCN.
Instead, we believe the E2 protection of eating behavior rhythms is enacted on a site
downstream of the SCN in the circadian system hierarchy. A future endeavor could
therefore remove or activate estrogen signaling via genetic models or pharmacological
routes in the various neural circuits that express ERs. Specifically, further investigation on
the ERα signaling mechanisms that regulate the daily eating behavior rhythms should be
prioritized, since we found that ERα is necessary for E2 protection of the eating rhythms
during HFD feeding (Ch4). ERα is co-localized in specific brain regions, such as the proopiomelanocortin (POMC) neurons and ventromedial hypothalamus (VMH), which have
been implicated in control of food intake and energy homeostasis487. ERα specific
antagonists such as methyl-piperidino-pyrazole (MPP) can be directly injected to these
regions via stereotaxic surgery488. Mice with Cre-mediated ERα KO in the hypothalamus
(POMC-Cre or VMH-Cre mice) can also be used for this study as they have been shown to
have increased food consumption and adiposity like whole-body ERαKO mice489. This can
help pinpoint the brain regions involved in the E2 protection of the daily eating rhythm in
females.
Our studies here show that the phase of the liver PER2::LUC rhythm was
advanced in female ERαKO mice, more so during HFD-feeding compared to chow (Ch 3
and 4). Liver-specific ERα knockout mice (LERαKO) can be used to help determine if the
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protective effect against HFD-induced dysregulation conferred by estrogen on the liver
clock in female mice is mediated by hepatic ERα. This type of study can help parse out
the mechanisms of diet-induced obesity. Previous studies have however shown that
female LERαKO mice have body weights similar to wild-type mice even when challenged
with HFD250. It is therefore possible that the phase of the liver clock is disrupted by HFDfeeding in LERαKO females, but the eating rhythm remains protected, hence the
protected body weight similar to WTs. This will show that local ERα signaling in the liver
is important to protect phase of the liver clock. And that some site upstream of the liver
(and possibly downstream of the site controlling eating behavior) is involved in the
protection of both the liver clock and diet-induced obesity in females.
2. Do other estrogen receptors, in addition to ERα, regulate daily rhythms in female mice fed
HFD?
It is also possible that although ERα regulates most mechanisms related to dietinduced obesity, both ERα and ERβ might have synergistic effects in the protection of
female mice from obesity. Thus, as an alternative approach, pharmacological activation
of ERβ with a selective agonist such as diarylpropionitrile (DPN) might therefore also be
useful to combat HFD-related disruption of daily rhythms. In fact, an ERβ isoformselective estrogen receptor ligand (β-LGNDs) has been shown to help prevent dietinduced obesity, reduce cholesterol, and improve glucose homeostasis in male and
female mice fed HFD254. DPN has also been shown to regulate certain parameters of the
activity rhythm in mice such as phase of activity248. It is possible that daily rhythms of
eating, locomotor and/or molecular rhythms are also protected via ERβ signaling
mechanisms.
3. Does exogenous estrogen regulate daily rhythm in male mice fed HFD?
Further studies also include studying the effects of exogenous estradiol on daily
rhythms of male mice during HFD feeding. Male mice lack circulating estrogens and their
daily rhythms are acutely affected by only 1 week of HFD feeding395. Just as seen in
female mice, loss of ERα signaling affects male metabolism. ERα KO male mice become
obese and are leptin resistant so they consume higher amounts of food490. They also
have increased lipogenesis that is associated with increased adiposity. Diet-induced
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obesity is prevented by estradiol treatment at high doses in male mice. In addition,
glucose homeostasis is unaffected by HFD feeding in estradiol-treated males491. Longterm estradiol treatment of intact male mice, however, does feminize male mice by
reducing the size of the accessory sex glands492. It will be interesting to know if estradiol
treatment is sufficient to protect daily rhythms from disruption by HFD feeding in male
mice.
In summary, this study demonstrates that regulation of daily metabolic rhythms by
circulating estrogens is an important mechanism by which females are protected from dietinduced obesity. Estrogen signaling via ERα is necessary for this protection against diet-induced
obesity and protection of daily rhythms of eating, locomotor, and PER2::LUC rhythms in tissues
of female mice. Estrogen signaling via ERα alone may also be sufficient in conferring these
protective mechanisms, or it may synergize with other ERs. Together, this study suggests that
the circadian system can be a target for treating obesity and its comorbidities in women after
menopause, when they lose circulating estrogens.
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APPENDICES
ARC

arcuate nucleus

AgRP

agouti-related peptide

AVPV

anteroventral periventricular nucleus

BMAL1

Brain and muscle Arnt-like 1

CCK

Cholecystokinin

CLOCK

circadian locomotor output cycles kaput

Cry

Cryptochrome

DD

constant darkness

DIO

diet-induced obesity

DMH

dorsomedial hypothalamus

DPN

diarylpropionitrile

E1

Estrone

E2

Estradiol

E3

Estriol

E4

Estetrol

ER

Estrogen receptor

ERE

Estrogen response element

ERα

Estrogen receptor alpha

ERβ

Estrogen receptor beta

GnRH

Gonadotropin hormone-releasing hormone

GPER1

G protein-coupled estrogen receptor 1

HFD

high-fat diet

ICV

Intracerebroventricular

ipRGCs

Intrinsically photosensitive retinal ganglion cells

KNDy

kisspeptin neurons co-expressing neurokinin B and dynorphin

neuropeptides
KO

knockout
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L:D

Light:dark

LepR

Leptin receptor

LERKO

Liver-specific ERα KO

LFD

low-fat diet

LL

constant light

MCH

melanin-concentrating hormone

NPY

neuropeptide Y

NTS

nucleus of the tractus solitarius

OVX

Ovariectomized

OXM

Oxyntomodulin

PER2::LUC

PERIOD2::LUCIFERASE

POA

medial preoptic area

POMC

pro-opiomelanocortin

PPT

propyl pyrazole triol

PRL

prolactin

PVN

paraventricular nucleus

PYY

Peptide YY

RHT

retino-hypothalamic tract

RP3V

rostral periventricular region of the third ventricle

SCN

suprachiasmatic nucleus

tRF

time-restricted feeding

TTFL

transcription and translation feedback loop

VMH

ventromedial hypothalamus

WT

wild-type

ZT

zeitgeiber time
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